

L8 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2002 ACS  
 AN 2002:449647 CAPLUS  
 DN 137:33212  
 TI Synthesis of fused pyrrolecarboxamides  
 IN Ragan, John Anthony  
 PA Pfizer Products Inc., USA  
 SO PCT Int. Appl., 23 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046155	A1	20020613	WO 2001-IB2104	20011108
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002010855	A5	20020618	AU 2002-10855	20011108
	US 2002151718	A1	20021017	US 2001-8294	20011203
PRAI	US 2000-250666P	P	20001204		
	WO 2001-IB2104	W	20011108		

OS CASREACT 137:33212; MARPAT 137:33212

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2002 ACS  
 AN 2002:185077 CAPLUS  
 DN 136:247488  
 TI Preparation of N-aryl-4-alkoximinoind(az)ole-3-carboxamides and analogs as GABAA receptor ligands  
 IN Maynard, George; Xie, Linghong; Rachwal, Stanislaw  
 PA Neurogen Corporation, USA  
 SO PCT Int. Appl., 115 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002020480	A1	20020314	WO 2001-US27643	20010906
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001090641	A5	20020322	AU 2001-90641	20010906
	US 2002128236	A1	20020912	US 2001-947710	20010906
PRAI	US 2000-230498P	P	20000906		
	WO 2001-US27643	W	20010906		

OS MARPAT 136:247488

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2002 ACS  
 AN 2001:758220 CAPLUS  
 DN 136:37466  
 TI Structural Determination of a Process Impurity in a Furan-Pyrrole  
 Heteroatom Exchange Reaction  
 AU Li, Bryan; Kasthurikrishnan, Narasimhan; Ragan, John A.; Young, Gregory R.  
 CS Chemical Research and Development, Pfizer Global Research and Development  
 Groton Laboratories, Groton, CT, 06340, USA  
 SO Organic Process Research & Development (2002), 6(1), 64-66  
 CODEN: OPRDFK; ISSN: 1083-6160  
 PB American Chemical Society  
 DT Journal  
 LA English  
 RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2002 ACS  
 AN 2001:241783 CAPLUS  
 DN 134:266200  
 TI Preparation of fused pyrrolicarboxamides as a new class of GABA brain  
 receptor ligands  
 IN Albaugh, Pamela; Liu, Gang; Shaw, Kenneth; Hutchison, Alan  
 PA Neurogen Corporation, USA  
 SO U.S., 26 pp., Cont.-in-part of U.S. 6,080,873  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6211365	B1	20010403	US 1999-387313	19990831
US 5804686	A	19980908	US 1996-588711	19960119
US 6080873	A	20000627	US 1998-148247	19980904
US 2001029299	A1	20011011	US 2001-801956	20010308
PRAI US 1996-588711	A1	19960119		
US 1998-148247	A2	19980904		
US 1999-387313	A1	19990831		

OS MARPAT 134:266200  
 RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2002 ACS  
 AN 2001:167966 CAPLUS  
 DN 134:207712  
 TI Preparation of fused pyrrolicarboxamides as GABA brain receptor ligands  
 IN Albaugh, Pamela; Shaw, Kenneth; Hutchison, Alan  
 PA Neurogen Corporation, USA  
 SO PCT Int. Appl., 194 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001016103	A1	20010308	WO 2000-US23862	20000830
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,				

CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 BR 2000013664 A 20020514 BR 2000-13664 20000830  
 EP 1210328 A1 20020605 EP 2000-959643 20000830  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL  
 NO 2002000948 A 20020228 NO 2002-948 20020227  
 PRAI US 1999-151789P P 19990831  
 US 1999-387311 A 19990831  
 WO 2000-US23862 W 20000830  
 OS MARPAT 134:207712  
 RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2002 ACS  
 AN 2000:814734 CAPLUS  
 DN 133:344635  
 TI Methods for screening GABA-modulatory compounds for cognitive-enhancing,  
 anxiolytic, hypnotic, or antidepressant activities  
 IN Tallman, John; Gallager, Dorothy; Shaw, Kenneth; White, Geoffrey;  
 Crandall, Marci; Cassella, James; Rajachandran, Lavanya; Albaugh, Pamela  
 PA Neurogen Corp., USA  
 SO PCT Int. Appl., 90 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000068691	A1	20001116	WO 2000-US12306	20000505
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,				
	CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,				
	ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,				
	LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,				
	SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,				
	ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				
	DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				
	CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1177445	A1	20020206	EP 2000-928860	20000505
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
	IE, SI, LT, LV, FI, RO				
	BR 2000010344	A	20020219	BR 2000-10344	20000505
	US 2002103108	A1	20020801	US 2001-45396	20011109
	US 2002115611	A1	20020822	US 2001-45230	20011109
	US 2002119911	A1	20020829	US 2001-45375	20011109
PRAI	US 1999-133154P	P	19990507		
	US 1999-133155P	P	19990507		
	US 1999-133191P	P	19990507		
	US 1999-133195P	P	19990507		
	US 2000-565524	A3	20000505		
	WO 2000-US12306	W	20000505		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2002 ACS  
 AN 1999:350648 CAPLUS  
 DN 130:352183  
 TI Method of synthesis of pyrrole amides  
 IN Ragan, John Anthony; Makowski, Teresa Woodall; Am Ende, David Jon;  
 Clifford, Pamela Jane; Young, Gregory Randall; Conrad, Alyson Kay;  
 Eisenbeis, Shane Allen; Quallich, George Joseph; Allen, Douglas John  
 Meldrum  
 PA Pfizer Products Inc., USA  
 SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9925684	A1	19990527	WO 1998-IB1672	19981021
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2310095	AA	19990527	CA 1998-2310095	19981021
	AU 9893639	A1	19990607	AU 1998-93639	19981021
	AU 745788	B2	20020328		
	EP 1030838	A1	20000830	EP 1998-946678	19981021
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
	BR 9814161	A	20000926	BR 1998-14161	19981021
	JP 2001523660	T2	20011127	JP 2000-521068	19981021
	ZA 9810350	A	20000512	ZA 1998-10350	19981112
	US 6262272	B1	20010717	US 1999-403985	19990119
	NO 2000002214	A	20000512	NO 2000-2214	20000428
PRAI	US 1997-65422P	P	19971113		
	US 1998-74266P	P	19980210		
	WO 1998-IB1672	W	19981021		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2002 ACS

AN 1998:306978 CAPLUS

DN 129:4586

TI Preparation of certain pyrrolopyridine-3-carboxamides as a new class of GABA brain receptor ligands

IN Albaugh, Pamela; Hutchison, Alan

PA Neurogen Corporation, USA

SO U.S., 23 pp., Cont.-in-part of U.S. 5,608,079.

CODEN: USXXAM

DT Patent  
LA English  
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5750702	A	19980512	US 1996-683066	19960716
	US 5484944	A	19960116	US 1993-144138	19931027
	EP 825193	A1	19980225	EP 1997-117241	19941026
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE			
	US 5608079	A	19970304	US 1995-473509	19950607
	WO 9802433	A1	19980122	WO 1997-US7830	19970509
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9728328	A1	19980209	AU 1997-28328	19970509
	WO 9802420	A1	19980122	WO 1997-US12153	19970714
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,			

LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,  
 RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN,  
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,  
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,  
 GN, ML, MR, NE, SN, TD, TG

AU 9736604	A1	19980209	AU 1997-36604	19970714
ZA 9706244	A	19990121	ZA 1997-6244	19970715
US 5925770	A	19990720	US 1998-73030	19980505
AU 9923799	A1	19990603	AU 1999-23799	19990416
AU 729634	B2	20010208		
PRAI US 1993-144138	A1	19931027		
US 1995-473509	A2	19950607		
AU 1994-81265	A3	19941026		
EP 1995-900440	A3	19941026		
US 1996-683066	A2	19960716		
WO 1997-US7830	W	19970509		
WO 1997-US12153	W	19970714		

OS MARPAT 129:4586

RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2002 ACS  
 AN 1998:157416 CAPLUS  
 DN 128:204804  
 TI Preparation of certain fused pyrrolocarboxamides as a new class of GABA  
 brain receptor ligands  
 IN Albaugh, Pamela; Liu, Gang; Hutchison, Alan  
 PA Neurogen Corp., USA  
 SO U.S., 19 pp.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5723462	A	19980303	US 1996-639166	19960426
	US 6096887	A	20000801	US 1998-31315	19980225
PRAI	US 1996-639166	A1	19960426		
OS	MARPAT 128:204804				

L8 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2002 ACS  
 AN 1998:71132 CAPLUS  
 DN 128:140608  
 TI Preparation of fused pyrrolocarboxamides as a new class of GABA brain  
 receptor ligands  
 IN Albaugh, Pamela; Liu, Gang; Hutchison, Alan  
 PA Neurogen Corporation, USA; Albaugh, Pamela; Liu, Gang; Hutchison, Alan  
 SO PCT Int. Appl., 58 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9802433	A1	19980122	WO 1997-US7830	19970509
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

	US 5750702	A	19980512	US 1996-683066	19960716
	AU 9728328	A1	19980209	AU 1997-28328	19970509
	AU 9923799	A1	19990603	AU 1999-23799	19990416
	AU 729634	B2	20010208		
PRAI	US 1996-683066	A2	19960716		
	US 1993-144138	A1	19931027		
	AU 1994-81265	A3	19941026		
	US 1995-473509	A2	19950607		
	WO 1997-US7830	W	19970509		
OS	MARPAT 128:140608				

L8 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2002 ACS  
AN 1998:66173 CAPLUS  
DN 128:140607  
TI Preparation of fused pyrrolocarboxanilides as a new class of GABA brain receptor ligands  
IN Albaugh, Pamela; Hutchison, Alan; Liu, Gang  
PA Hutchison, Alan, USA; Liu, Gang; Neurogen Corporation; Albaugh, Pamela  
SO PCT Int. Appl., 86 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9802420	A1	19980122	WO 1997-US12153	19970714
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5750702	A	19980512	US 1996-683066	19960716
	AU 9736604	A1	19980209	AU 1997-36604	19970714
	AU 9923799	A1	19990603	AU 1999-23799	19990416
	AU 729634	B2	20010208		
PRAI	US 1996-683066	A2	19960716		
	US 1993-144138	A1	19931027		
	AU 1994-81265	A3	19941026		
	US 1995-473509	A2	19950607		
	WO 1997-US12153	W	19970714		
OS	MARPAT 128:140607				

L8 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2002 ACS  
AN 1997:640642 CAPLUS  
DN 127:307298  
TI Preparation of fused pyrrolocarboxamides as GABA brain receptor ligands  
IN Albaugh, Pamela; Liu, Gang; Hutchison, Alan  
PA Neurogen Corp., USA; Albaugh, Pamela; Liu, Gang; Hutchison, Alan  
SO PCT Int. Appl., 46 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9734870	A1	19970925	WO 1997-US4623	19970320
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,  
 GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,  
 ML, MR, NE, SN, TD, TG

CA 2249562	AA	19970925	CA 1997-2249562	19970320
AU 9722189	A1	19971010	AU 1997-22189	19970320
EP 888300	A1	19990107	EP 1997-915182	19970320

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, FI

US 2001020035	A1	20010906	US 1998-88522	19980601
US 6353109	B2	20020305		

PRAI US 1996-620939 A2 19960322  
 WO 1997-US4623 W 19970320  
 OS MARPAT 127:307298



L8 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2002 ACS  
 AN 1997:499171 CAPLUS  
 DN 127:190644  
 TI Preparation of fused pyrrolocarboxamides as GABA brain receptor ligands.  
 IN Albaugh, Pamela; Liu, Gang; Shaw, Kenneth; Hutchison, Alan  
 PA Neurogen Corp., USA; Albaugh, Pamela; Liu, Gang; Shaw, Kenneth; Hutchison,  
 Alan  
 SO PCT Int. Appl., 51 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9726243	A1	19970724	WO 1997-US519	19970114
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5804686	A	19980908	US 1996-588711	19960119
	CA 2243317	AA	19970724	CA 1997-2243317	19970114
	AU 9717466	A1	19970811	AU 1997-17466	19970114
	CN 1209805	A	19990303	CN 1997-191759	19970114
	BR 9707051	A	19990720	BR 1997-7051	19970114
	JP 2000503321	T2	20000321	JP 1997-526110	19970114
	EP 1019372	A1	20000719	EP 1997-904754	19970114
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	RU 2167151	C2	20010520	RU 1998-115534	19970114
	ZA 9708292	A	19980525	ZA 1997-8292	19970915
	NO 9803315	A	19980903	NO 1998-3315	19980717
PRAI	US 1996-588711	A1	19960119		
	WO 1997-US519	W	19970114		
OS	MARPAT 127:190644				

L8 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2002 ACS  
 AN 1995:823078 CAPLUS  
 DN 123:313756  
 TI Preparation of annelated pyrrolocarboxanilides as GABA brain receptor  
 ligands  
 IN Albaugh, Pamela; Hutchison, Alan  
 PA Neurogen Corp., USA  
 SO PCT Int. Appl., 66 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9511885	A1	19950504	WO 1994-US12300	19941026
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5484944	A	19960116	US 1993-144138	19931027
	CA 2175204	AA	19950511	CA 1994-2175204	19941026
	AU 9481265	A1	19950522	AU 1994-81265	19941026
	AU 701151	B2	19990121		
	EP 725775	A1	19960814	EP 1995-900440	19941026
	EP 725775	B1	19980722		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	CN 1143953	A	19970226	CN 1994-194657	19941026
	JP 09506082	T2	19970617	JP 1994-512807	19941026
	HU 76064	A2	19970630	HU 1996-1106	19941026
	HU 219715	B	20010628		
	EP 825193	A1	19980225	EP 1997-117241	19941026
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	AT 168673	E	19980815	AT 1995-900440	19941026
	ES 2122504	T3	19981216	ES 1995-900440	19941026
	RU 2125989	C1	19990210	RU 1996-110289	19941026
	RU 2157367	C2	20001010	RU 1998-115589	19941026
	PL 180027	B1	20001229	PL 1994-314136	19941026
	CZ 288027	B6	20010411	CZ 1996-1129	19941026
	SE 9601563	A	19960522	SE 1996-1563	19960424
	NO 9601655	A	19960610	NO 1996-1655	19960425
	FI 9601776	A	19960614	FI 1996-1776	19960425
	AU 9923799	A1	19990603	AU 1999-23799	19990416
	AU 729634	B2	20010208		
	SE 9902648	A	19990709	SE 1999-2648	19990709
PRAI	US 1993-144138	A2	19931027		
	AU 1994-81265	A3	19941026		
	EP 1995-900440	A3	19941026		
	WO 1994-US12300	W	19941026		
OS	MARPAT 123:313756				



chain nodes :

10 11 12 13 14 15 16 17

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

4-10 7-15 9-14 11-15 12-13 12-15 12-16 16-17

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :

4-10 6-9 8-9 11-15 12-15 12-16 16-17

exact bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-7 7-8 7-15 9-14 12-13

isolated ring systems :

containing 1 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS  
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:Atom 17:CLASS

=> d 18 bib abs hitstr 1-14

L8 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2002 ACS  
AN 2002:449647 CAPLUS  
DN 137:33212  
TI Synthesis of fused pyrrolocarboxamides  
IN Ragan, John Anthony  
PA Pfizer Products Inc., USA  
SO PCT Int. Appl., 23 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

*applicant's own*

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046155	A1	20020613	WO 2001-IB2104	20011108
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002010855	A5	20020618	AU 2002-10855	20011108
	US 2002151718	A1	20021017	US 2001-8294	20011203
PRAI	US 2000-250666P	P	<u>20001204</u>		
	WO 2001-IB2104	W	20011108		
OS	CASREACT 137:33212; MARPAT 137:33212				
GI					




AB The title compds. [I; Ar = (un)substituted Ph, heterocycle; R3 = H, alkyl; n = 0-2] which selectively bind to GABA<sub>A</sub> receptors (no biol. data), were prepd. by reacting 1,3-cycloalkanediones with Et bromoacetate followed by reaction of the resulting product with an acid halide followed by reaction with an arom. amine and finally with an ammonium source at an elevated temp. Thus, treating 4,5,6,7-tetrahydrobenzofuran-3-carboxylic acid with Et<sub>3</sub>N and ClCO<sub>2</sub>Et in CH<sub>2</sub>Cl<sub>2</sub> followed by addn. of methyl-[1-(4-aminophenyl)ethyl]carbamic acid tert-Bu ester (ca. 100% yield), reacting the resulting 4,5,6,7-tetrahydrobenzofuran-3-carboxamide with NH<sub>2</sub>OAc in NMP (80%), and treating the resulting 4,5,6,7-tetrahydro-1H-indole-3-carboxamide with HCl afforded I [Ar = 4-(MeNHCHMe)C<sub>6</sub>H<sub>4</sub>; R3 = H; n = 1].

IT 202206-38-0P 329016-43-5P 329017-94-9P  
436085-52-8P 436085-53-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(synthesis of fused pyrrolocarboxamides)


RN 202206-38-0 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-(2-fluoro-4-hydroxyphenyl)-  
1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-43-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(propylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329017-94-9 CAPLUS

CN Acetic acid, [2-fluoro-4-[[4,5,6,7-tetrahydro-4-oxo-1H-indol-3-yl)carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 436085-52-8 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[1-(methylamino)ethyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 436085-53-9 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-(2-aminopropyl)phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



IT 329017-93-8P 436085-55-1P 436085-62-0P


436085-64-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of fused pyrrolocarboxamides)


RN 329017-93-8 CAPLUS

CN Acetic acid, [2-fluoro-4-[[[(4,5,6,7-tetrahydro-4-oxo-1H-indol-3-yl)carbonyl]amino]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 436085-55-1 CAPLUS


CN Carbamic acid, methyl [1-[4-[[[(4,5,6,7-tetrahydro-4-oxo-1H-indol-3-yl)carbonyl]amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 436085-62-0 CAPLUS


CN Carbamic acid, [1-methyl-2-[4-[[[(4,5,6,7-tetrahydro-4-oxo-1H-indol-3-yl)carbonyl]amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 436085-64-2 CAPLUS

CN Carbamic acid, propyl [2-[4-[[[(4,5,6,7-tetrahydro-4-oxo-1H-indol-3-yl)carbonyl]amino]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




IT 436085-57-3P 436085-58-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(synthesis of fused pyrrolocarboxamides)


RN 436085-57-3 CAPLUS


CN Carbamic acid, [2-[2-fluoro-4-[[[(4,5,6,7-tetrahydro-4-oxo-1H-indol-3-yl)carbonyl]amino]phenoxy]ethyl]propyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 436085-58-4 CAPLUS

CN Carbamic acid, butyl [2-[[5-[[[(4,5,6,7-tetrahydro-4-oxo-1H-indol-3-yl)carbonyl]amino]-2-pyridinyl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)






RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2002 ACS  
AN 2002:185077 CAPLUS  
DN 136:247488  
TI Preparation of N-aryl-4-alkoximinoin(d)azole-3-carboxamides and analogs as  
GABAA receptor ligands  
IN Maynard, George; Xie, Linghong; Rachwal, Stanislaw  
PA Neurogen Corporation, USA  
SO PCT Int. Appl., 115 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002020480	A1	20020314	WO 2001-US27643	20010906
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				
	LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,				
	PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,				
	US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2001090641	A5	20020322	AU 2001-90641	20010906
	US 2002128236	A1	20020912	US 2001-947710	20010906
PRAI	US 2000-230498P	P	20000906		
	WO 2001-US27643	W	20010906		
OS	MARPAT 136:247488				
GI					

09/947,710  
not claimed




AB Title compds. [I; R = OH, hydrocarb(yl)oxy, aryl(oxy), etc.; R1 = H or 1-4 of halo, NH2, hydrocarb(yl)oxy, etc.; R2 = (un)substituted (hetero)aryl; Z = bond, (un)substituted CH2, -CH2CH2; Z1 = N or CR3; R3 = H or hydrocarb(yl)] were prep'd. as GABAA receptor ligands (no data). Thus, cyclohexane-1,3-dione was cyclocondensed with BrCH2COCOC2Et to give, in 2 addnl. steps, 4-oxo-4,5,6,7-tetrahydroindole-3-carboxylic acid which was amidated by 2-FC6H4NH2 to give, after oximation, I (R = OMe, R1 = H, R2 = C6H4F-2, Z = CH2, Z1 = CH).


IT 168271-93-0P 168272-47-7P 194098-24-3P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. of N-aryl-4-alkoximinind(az)ole-3-carboxamides and analogs as  
 GABAA receptor ligands)  
 RN 168271-93-0 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-methoxyphenyl)-4-oxo-  
 (9CI) (CA INDEX NAME)



RN 168272-47-7 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(2-fluorophenyl)-4,5,6,7-tetrahydro-4-oxo-  
 (9CI) (CA INDEX NAME)




RN 194098-24-3 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[3-  
 [(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



*specification only  
 date is no good*

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2002 ACS  
 AN 2001:758220 CAPLUS  
 DN 136:37466  
 TI Structural Determination of a Process Impurity in a Furan-Pyrrole  
 Heteroatom Exchange Reaction  
 AU Li, Bryan; Kasthurikrishnan, Narasimhan; Ragan, John A.; Young, Gregory R.  
 CS Chemical Research and Development, Pfizer Global Research and Development  
 Groton Laboratories, Groton, CT, 06340, USA  
 SO Organic Process Research & Development (2002), 6(1), 64-66  
 CODEN: OPRDFK; ISSN: 1083-6160  
 PB American Chemical Society  
 DT Journal  
 LA English  
 GI



I


AB Electron-deficient pyrrole I [X = NH, R = H], prepd. by reaction of I [X = O, R = H] with NH<sub>4</sub>OAc, was derivatized by diazotization with p-nitrobenzenediazonium chloride. Redn. of the diazo intermediates gave I [X = NH, R = NH<sub>2</sub>; X = NNH<sub>2</sub>, R = H]. I [X = NH, R = NH<sub>2</sub>] was detd. to be the process impurity formed during the conversion of I [X = O, R = H] to I [X = NH, R = H]. An oxidative mechanism for the impurity formation was hypothesized. Nitrogen sparging of the reaction mixt. prior to heating eliminated formation of I [X = NH, R = NH<sub>2</sub>].

IT 168272-59-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(formation of a 2-amino deriv. in the prepn. of a cycloheptapyrrole from cycloheptafuran)

RN 168272-59-1 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-(2-fluoro-4-methoxyphenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




IT 380365-94-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(formation of a 2-amino deriv. in the prepn. of a cycloheptapyrrole from cycloheptafuran)

RN 380365-94-6 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 2-amino-N-(2-fluoro-4-methoxyphenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2002 ACS

AN 2001:241783 CAPLUS


DN 134:266200

TI Preparation of fused pyrrolicarboxamides as a new class of GABA brain

receptor ligands

IN Albaugh, Pamela; Liu, Gang; Shaw, Kenneth; Hutchison, Alan  
PA Neurogen Corporation, USA  
SO U.S., 26 pp., Cont.-in-part of U.S. 6,080,873.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6211365	B1	20010403	US 1999-387313	19990831
	US 5804686	A	19980908	US 1996-588711	19960119
	US 6080873	A	20000627	US 1998-148247	19980904
	US 2001029299	A1	20011011	US 2001-801956	20010308
PRAI	US 1996-588711	A1	19960119		
	US 1998-148247	A2	19980904		
	US 1999-387313	A1	19990831		
OS	MARPAT 134:266200				
GI					



AB The title compds. [I; G = substituted Ph, etc.; T = halo, H, OH, etc.; X = H, OH, alkyl; R3-R6 = H, alkyl, CO(alkyl), etc.; n = 0-3] which compds. are highly selective agonists, antagonists or inverse agonists for GABA<sub>A</sub> brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA<sub>A</sub> brain receptors, and therefore are useful in the diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory, were prepd. E.g., a multi-step synthesis of I [G = 3-(MeNHCH<sub>2</sub>)C<sub>6</sub>H<sub>4</sub>; T, X = H; R3-R6 = H; n = 1] which showed K<sub>i</sub> of 90 nM against GABA<sub>A</sub> receptor binding, was given.


IT 168272-49-9P 194098-30-1P 194098-35-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of fused pyrrolecarboxamides as a new class of GABA brain receptor ligands)

RN 168272-49-9. CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(2-hydroxyethoxy)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 194098-30-1 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[[1-

methylethyl) amino] methyl] phenyl] -4-oxo- (9CI) (CA INDEX NAME)



RN 194098-35-6 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[4-[(methylethylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




IT 168272-20-6P 194098-24-3P 194098-25-4P  
 194098-26-5P 194098-27-6P 194098-28-7P  
 194098-29-8P 194098-31-2P 194098-32-3P  
 194098-33-4P 194098-34-5P 194098-36-7P  
 194098-37-8P 194098-38-9P 194098-39-0P  
 194098-40-3P 194098-41-4P 194098-42-5P  
 194098-43-6P 194098-44-7P 194098-53-8P  
 194098-59-4P 194098-92-5P 329016-27-5P  
 329016-39-9P 329016-41-3P 329016-43-5P  
 329016-46-8P 329016-48-0P 329016-50-4P  
 329016-51-5P 329016-53-7P 329016-55-9P  
 329016-56-0P 329016-58-2P 329016-60-6P  
 329016-62-8P 329016-63-9P 329016-64-0P  
 329016-66-2P 329016-67-3P 329016-68-4P  
 329016-69-5P 329016-70-8P 329016-72-0P  
 329016-82-2P 329016-84-4P 329016-86-6P  
 329016-88-8P 329016-89-9P 329016-91-3P  
 329016-93-5P 329016-95-7P 329016-96-8P  
 329016-97-9P 329016-98-0P 329016-99-1P  
 329017-00-7P 329017-01-8P 329017-02-9P  
 329017-06-3P 329017-07-4P 329017-56-3P  
 329017-60-9P 329017-67-6P 329017-69-8P  
 329017-73-4P 329017-79-0P 329017-93-8P  
 329017-94-9P 329017-96-1P 329017-99-4P  
 329018-00-0P 329018-01-1P 329018-02-2P  
 329018-03-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of fused pyrrolicarboxamides as a new class of GABA brain receptor ligands)


RN 168272-20-6 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(methoxymethyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-24-3 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[3-  
[(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-25-4 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-  
[(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-26-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-(aminomethyl)phenyl]-4,5,6,7-tetrahydro-4-  
oxo- (9CI) (CA INDEX NAME)




RN 194098-27-6 CAPLUS


CN 1H-Indole-3-carboxamide, N-[2-fluoro-4-[(methylamino)methyl]phenyl]-  
4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-28-7 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-[4-[(acetylmethylamino)methyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-29-8 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-[4-[(ethylamino)methyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-31-2 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-[4-[(cyclopropylamino)methyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-32-3 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-[4-[(dimethylamino)methyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-33-4 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-[4-(2-aminoethyl)phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-34-5 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-(methylamino)ethyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-36-7 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-[4-[(acetylmethylamino)methyl]phenyl]-4,5,6,7-tetrahydro-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-37-8 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-6-methyl-N-[4-[(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-38-9 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(hydroxymethyl)phenyl]-6-methyl-4-oxo- (9CI) (CA INDEX NAME)






RN 194098-39-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(2-hydroxyethoxy)phenyl]-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-40-3 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-6-methyl-N-[3-[(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-41-4 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(2-hydroxyethoxy)phenyl]-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-42-5 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[3-(hydroxymethyl)phenyl]-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)



RN 194098-43-6 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(hydroxymethyl)phenyl]-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-44-7 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-6,6-dimethyl-N-[4-[(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




103


RN 194098-53-8 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(2,2-dimethyl-1,3-benzodioxol-5-yl)-4,5,6,7-tetrahydro-6-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 194098-59-4 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[6-(2-hydroxyethoxy)-3-pyridinyl]-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-92-5 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-(methylamino)ethoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-27-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329016-39-9 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(1-pyrrolidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329016-41-3 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-(ethylamino)ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-43-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(propylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 329016-46-8 CAPLUS


CN 1H-Indole-3-carboxamide, N-[3-fluoro-4-[2-(propylamino)ethoxy]phenyl]-  
4,5,6,7-tetrahydro-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 329016-48-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-[(1-methylethyl)amino]ethoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-50-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[(cyclopropylmethyl)amino]ethoxy]phenyl]-  
4,5,6,7-tetrahydro-4-oxo-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX  
NAME)

CM 1

CRN 329016-49-1

CMF C21 H25 N3 O3




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.



RN 329016-51-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[(cyclopropylmethyl)amino]ethoxy]-2-fluorophenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-53-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[(cyclopropylmethyl)amino]ethoxy]-3-fluorophenyl]-4,5,6,7-tetrahydro-4-oxo-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 329016-52-6


CMF C21 H24 F N3 O3



CM 2


CRN 104-15-4

CMF C7 H8 O3 S




RN 329016-55-9 CAPLUS

CN 1H-Indole-3-carboxamide, N-[2-fluoro-4-[2-[(2-methylpropyl)amino]ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-56-0 CAPLUS

CN 1H-Indole-3-carboxamide, N-[3-fluoro-4-[2-[(2-methylpropyl)amino]ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 329016-58-2 CAPLUS


CN 1H-Indole-3-carboxamide, N-[4-[2-(butylamino)ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329016-60-6 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[(1,1-dimethylethyl)amino]ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 329016-62-8 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(tricyclo[3.3.1.1.3,7]dec-2-ylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 329016-63-9 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[(2R)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329016-64-0 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[(2S)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 329016-66-2 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-(3-piperidylmethoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329016-67-3 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-(dimethylamino)ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-68-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-(dimethylamino)ethoxy]-3-fluorophenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-69-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-70-8 CAPLUS

CN 1H-Indole-3-carboxamide, N-[3-fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-72-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(2-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 329016-82-2 CAPLUS


CN 1H-Indole-3-carboxamide, N-[4-[2-(ethylamino)ethoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 329016-84-4 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(propylamino)ethoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 329016-86-6 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-[(1-methylethyl)amino]ethoxy]-3-pyridinyl]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 329016-88-8 CAPLUS


CN 1H-Indole-3-carboxamide, N-[4-[2-(butylamino)ethoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329016-89-9 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[(1,1-dimethylethyl)amino]ethoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-91-3 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-[(phenylmethyl)amino]ethoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 329016-93-5 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-(3-pyridinylmethoxy)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329016-95-7 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-(4-pyridinylmethoxy)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329016-96-8 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[(2R)-2-pyrrolidinylmethoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 329016-97-9 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[(2R)-2-pyrrolidinylmethoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 329016-98-0 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[(2S)-2-pyrrolidinylmethoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 329016-99-1 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-(dimethylamino)ethoxy]-3-pyridinyl]-  
4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-00-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[3-(dimethylamino)propoxy]-3-pyridinyl]-  
4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-01-8 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(1-pyrrolidinyl)ethoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 329017-02-9 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(1-pyrrolidinyl)ethoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 329017-06-3 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(1-piperidinyl)ethoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329017-07-4 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[(1-methyl-3-pyrrolidinyl)methoxy]-3-pyridinyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-56-3 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[3-[3-(tricyclo[3.3.1.1.3,7]dec-1-ylamino)propoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 329017-60-9 CAPLUS


CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-[2-(ethylamino)ethoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329017-67-6 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[4-(3-pyridinylmethoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 329017-69-8 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[4-(4-pyridinylmethoxy)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl



● HCl

RN 329017-73-4 CAPLUS


CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[4-[2-(1-pyrrolidinyl)ethoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 329017-79-0 CAPLUS


CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[4-[2-(propylamino)ethoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329017-93-8 CAPLUS

CN Acetic acid, [2-fluoro-4-[[4,5,6,7-tetrahydro-4-oxo-1H-indol-3-yl]carbonyl]amino]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 329017-94-9 CAPLUS

CN Acetic acid, [2-fluoro-4-[[4,5,6,7-tetrahydro-4-oxo-1H-indol-3-yl]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 329017-96-1 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-(diethylamino)-2-oxoethoxy]-3-fluorophenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-99-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[[2-(dipropylamino)ethyl]amino]-2-oxoethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-00-0 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[[2-(diethylamino)ethyl]methylamino]-2-oxoethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-01-1 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[[2-(diethylamino)ethyl]ethylamino]-2-oxoethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-02-2 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 329018-03-3 CAPLUS

CN 1H-Indole-3-carboxamide, N-[3-fluoro-4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



IT 168271-95-2 168272-15-9 168272-28-4


168272-41-1

RL: PRP (Properties)

(prepn. of fused pyrrolicarboxamides as a new class of GABA brain receptor ligands)


RN 168271-95-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-15-9 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-fluorophenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-28-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-methoxyphenyl)-4,5,6,7-tetrahydro-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)



RN 168272-41-1 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2002 ACS

AN 2001:167966 CAPLUS

DN 134:207712

TI Preparation of fused pyrrolocarboxamides as GABA brain receptor ligands

IN Albaugh, Pamela; Shaw, Kenneth; Hutchison, Alan

PA Neurogen Corporation, USA

SO PCT Int. Appl., 194 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001016103	A1	20010308	WO 2000-US23862	20000830
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000013664	A	20020514	BR 2000-13664	20000830
	EP 1210328	A1	20020605	EP 2000-959643	20000830
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	NO 2002000948	A	20020228	NO 2002-948	20020227
PRAI	US 1999-151789P	P	19990831		
	US 1999-387311	A	19990831		
	WO 2000-US23862	W	20000830		
OS	MARPAT 134:207712				
GI					

date no good



09/387,311

AB

AB Substituted pyrrolecarboxamide compds. [I; T = halogen, hydrogen, hydroxy, amino, alkyl or alkoxy; X = hydrogen, hydroxy, amino, benzyl, tert-butoxycarbonyl, benzyloxycarbonyl, alkyl, or alkoxy; G = -Q-(CH<sub>2</sub>)<sub>k</sub>-W-(CH<sub>2</sub>)<sub>m</sub>-Z; where Q = an optionally substituted aryl or optionally substituted heteroaryl group having from 1 to 3 rings, 3 to 8 members in each ring and from 1 to 3 heteroatoms; W = hydrogen, O, NH, NR<sub>7</sub>, S(O)O<sub>0-2</sub>, CO, OC(O), C(O)O, C(O)NH, NHC(O), NR<sub>7</sub>C(O), NHS(O)O<sub>0-2</sub>, NR<sub>7</sub>S(O)O<sub>0-2</sub>, S(O)O<sub>0-2</sub>NH, S(O)O<sub>0-2</sub>NR<sub>7</sub>, and CR<sub>7</sub>R<sub>8</sub>; where R<sub>7</sub>, R<sub>8</sub> = hydrogen or alkyl, or CR<sub>7</sub>R<sub>8</sub> = a cyclic moiety having 3-7 carbon atoms; Z = hydrogen, hydroxy, cycloalkyl(alkoxy), amino, mono- or di(alkyl)amino, azacycloalkyl, O(alkyl), S(O)O<sub>0-2</sub>(alkyl), C(O)(alkyl), OC(O)(alkyl), OC(O)H, C(O)O(alkyl), C(O)OH, C(O)NH(alkyl), etc.; R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> = hydrogen, alkyl, COR<sub>11</sub> or CO<sub>2</sub>R<sub>11</sub> (where R<sub>11</sub> = alkyl or cycloalkyl having 3-7 carbon atoms), CONR<sub>12</sub>R<sub>13</sub> (where R<sub>12</sub>, R<sub>13</sub> = hydrogen, alkyl, cycloalkyl having 3-7 carbon atoms, Ph, 2-, 3-, or 4-pyridyl, or NR<sub>12</sub>R<sub>13</sub> forms a heterocyclic group), etc.; or R<sub>3</sub> and R<sub>4</sub> together with the carbon atom to which they are attached form a cyclic moiety having 3-7 carbon atoms] are disclosed. These compds. are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Alzheimer's dementia, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compns., including packaged pharmaceutical compns., are further provided. Compds. of the invention are also useful as probes for the localization of GABAA receptors in tissue samples. Thus, To a stirred soln. of 4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid (100 mg, 0.6 mmol) and Et<sub>3</sub>N (0.15 mL, 1.1 mmol) in DMF (5 mL) at 0.degree. is added Et chloroformate (0.1 mL, 1.1 mmol), stirred for 1 h, treated with

3-[N-trifluoroacetyl(methylaminomethyl)]aniline (0.3 g, 1.3 mmol), and the reaction mixt. was stirred for 4 h to give, after workup, N-[3-(methylaminomethyl)phenyl]-4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxamide (II). II and N-[4-(2-methylaminoethyl)phenyl]-4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxamide showed binding affinity for GABAA receptor with  $K_i$  of 90 and 0.24, resp., in a binding assay described by Thomas and Tallman (J. Bio. Chem. 1981 and J. Neurosci. 1983).


IT 168272-20-6P 168272-49-9P 168272-51-3P  
 194098-24-3P 194098-25-4P 194098-26-5P  
 194098-27-6P 194098-28-7P 194098-29-8P  
 194098-30-1P 194098-31-2P 194098-32-3P  
 194098-33-4P 194098-34-5P 194098-35-6P  
 194098-36-7P 194098-37-8P 194098-38-9P  
 194098-39-0P 194098-40-3P 194098-41-4P  
 194098-42-5P 194098-43-6P 194098-44-7P  
 194098-53-8P 194098-59-4P 194098-92-5P  
 329016-27-5P 329016-28-6P 329016-29-7P  
 329016-30-0P 329016-31-1P 329016-32-2P  
 329016-33-3P 329016-34-4P 329016-35-5P  
 329016-36-6P 329016-37-7P 329016-38-8P  
 329016-39-9P 329016-40-2P 329016-41-3P  
 329016-42-4P 329016-43-5P 329016-44-6P  
 329016-45-7P 329016-46-8P 329016-47-9P  
 329016-48-0P 329016-49-1P 329016-50-4P  
 329016-51-5P 329016-52-6P 329016-53-7P  
 329016-54-8P 329016-55-9P 329016-56-0P  
 329016-57-1P 329016-58-2P 329016-59-3P  
 329016-60-6P 329016-61-7P 329016-62-8P  
 329016-63-9P 329016-64-0P 329016-65-1P  
 329016-66-2P 329016-67-3P 329016-68-4P  
 329016-69-5P 329016-70-8P 329016-71-9P  
 329016-72-0P 329016-73-1P 329016-74-2P  
 329016-75-3P 329016-76-4P 329016-77-5P  
 329016-78-6P 329016-79-7P 329016-80-0P  
 329016-81-1P 329016-82-2P 329016-83-3P  
 329016-84-4P 329016-85-5P 329016-86-6P  
 329016-87-7P 329016-88-8P 329016-89-9P  
 329016-90-2P 329016-91-3P 329016-92-4P  
 329016-93-5P 329016-94-6P 329016-95-7P  
 329016-96-8P 329016-97-9P 329016-98-0P  
 329016-99-1P 329017-00-7P 329017-01-8P  
 329017-02-9P 329017-03-0P 329017-04-1P  
 329017-05-2P 329017-06-3P 329017-07-4P  
 329017-08-5P 329017-09-6P 329017-10-9P  
 329017-11-0P 329017-12-1P 329017-13-2P  
 329017-14-3P 329017-15-4P 329017-16-5P  
 329017-17-6P 329017-18-7P 329017-19-8P  
 329017-20-1P 329017-21-2P 329017-22-3P  
 329017-23-4P 329017-24-5P 329017-25-6P  
 329017-26-7P 329017-27-8P 329017-28-9P  
 329017-29-0P 329017-30-3P 329017-31-4P  
 329017-32-5P 329017-33-6P 329017-34-7P  
 329017-35-8P 329017-36-9P 329017-37-0P  
 329017-38-1P 329017-39-2P 329017-40-5P  
 329017-41-6P 329017-42-7P 329017-43-8P  
 329017-44-9P 329017-45-0P 329017-46-1P  
 329017-47-2P 329017-48-3P 329017-49-4P  
 329017-50-7P 329017-51-8P 329017-52-9P  
 329017-53-0P 329017-54-1P 329017-55-2P  
 329017-56-3P 329017-57-4P 329017-58-5P  
 329017-59-6P 329017-60-9P 329017-61-0P  
 329017-62-1P 329017-63-2P 329017-64-3P  
 329017-65-4P 329017-66-5P 329017-67-6P  
 329017-68-7P 329017-69-8P 329017-70-1P

329017-71-2P 329017-72-3P 329017-73-4P  
 329017-74-5P 329017-75-6P 329017-76-7P  
 329017-77-8P 329017-78-9P 329017-79-0P  
 329017-80-3P 329017-81-4P 329017-82-5P  
 329017-83-6P 329017-84-7P 329017-85-8P  
 329017-86-9P 329017-87-0P 329017-88-1P  
 329017-89-2P 329017-90-5P 329017-91-6P  
 329017-92-7P 329017-93-8P 329017-94-9P  
 329017-95-0P 329017-96-1P 329017-97-2P  
 329017-98-3P 329017-99-4P 329018-00-0P  
 329018-01-1P 329018-02-2P 329018-03-3P  
 329018-04-4P 329018-05-5P 329018-06-6P  
 329018-07-7P 329018-08-8P 329018-09-9P  
 329018-10-2P 329018-11-3P 329018-13-5P  
 329018-20-4P 329018-21-5P 329018-22-6P  
 329018-23-7P 329018-24-8P 329018-25-9P  
 329018-26-0P 329018-27-1P 329018-28-2P  
 329018-29-3P 329018-30-6P 329018-31-7P  
 329018-32-8P 329018-33-9P 329018-34-0P  
 329018-35-1P 329018-36-2P 329018-37-3P  
 329018-38-4P 329018-39-5P 329018-40-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of fused pyrrolicarboxamides as GABA brain receptor ligands for treatment of central nervous system diseases)


RN 168272-20-6 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(methoxymethyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-49-9 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(2-hydroxyethoxy)phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-51-3 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(2-methoxyethoxy)phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-24-3 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[3-[(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-25-4 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 194098-26-5 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-[4-(aminomethyl)phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-27-6 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-[2-fluoro-4-[(methylamino)methyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-28-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[(acetylmethylamino)methyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-29-8 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[(ethylamino)methyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-30-1 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[[1-methylethyl)amino]methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-31-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[(cyclopropylamino)methyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-32-3 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[(dimethylamino)methyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-33-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-(2-aminoethyl)phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-34-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-(methylamino)ethyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-35-6 CAPLUS


CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[4-[(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 194098-36-7 CAPLUS


CN 1H-Indole-3-carboxamide, N-[4-[(acetylmethylamino)methyl]phenyl]-4,5,6,7-tetrahydro-6-methyl-4-oxo- (9CI) (CA INDEX NAME)






RN 194098-37-8 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-6-methyl-N-[4-[(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-38-9 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(hydroxymethyl)phenyl]-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-39-0 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(2-hydroxyethoxy)phenyl]-6-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 194098-40-3 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-6-methyl-N-[3-[(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)






RN 194098-41-4 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(2-hydroxyethoxy)phenyl]-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-42-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[3-(hydroxymethyl)phenyl]-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-43-6 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(hydroxymethyl)phenyl]-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-44-7 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-6,6-dimethyl-N-[4-[(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-53-8 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2,2-dimethyl-1,3-benzodioxol-5-yl)-4,5,6,7-tetrahydro-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-59-4 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[6-(2-hydroxyethoxy)-3-pyridinyl]-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-92-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-(methylamino)ethoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-27-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329016-28-6 CAPLUS

CN 1H-Indole-3-carboxamide, N-[3-[2-(dimethylamino)ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-29-7 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[3-[2-(propylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329016-30-0 CAPLUS

CN 1H-Indole-3-carboxamide, N-[3-[2-(butylamino)ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-31-1 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[3-[2-[(2-methylpropyl)amino]ethoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-32-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-[3-[2-(cyclobutylamino)ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-33-3 CAPLUS

CN 1H-Indole-3-carboxamide, N-[3-[2-[(1,1-dimethylethyl)amino]ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-34-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-[3-[2-[(cyclopropylmethyl)amino]ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-35-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[3-[2-[(4-methylcyclohexyl)amino]ethoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-36-6 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[3-[2-[[[3-(trifluoromethyl)phenyl]methyl]amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329016-37-7 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[3-[3-[[[3-(trifluoromethyl)phenyl]methyl]amino]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329016-38-8 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-(dimethylamino)ethyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-39-9 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(1-pyrrolidinyl)ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329016-40-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-41-3 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-(ethylamino)ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-42-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-(ethylamino)ethoxy]-2-fluorophenyl]-  
4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-43-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(propylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329016-44-6 CAPLUS

CN 1H-Indole-3-carboxamide, N-[2-fluoro-4-[2-(propylamino)ethoxy]phenyl]-  
4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-45-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-[3-fluoro-4-[2-(propylamino)ethoxy]phenyl]-  
4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 329016-46-8 CAPLUS


CN 1H-Indole-3-carboxamide, N-[3-fluoro-4-[2-(propylamino)ethoxy]phenyl]-  
4,5,6,7-tetrahydro-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329016-47-9 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-(cyclopropylamino)ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-48-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-[(1-methylethyl)amino]ethoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 329016-49-1 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[(cyclopropylmethyl)amino]ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-50-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[(cyclopropylmethyl)amino]ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo-, (2E)-2-butenedioate (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 329016-49-1

CMF C21 H25 N3 O3




CM 2

CRN 110-17-8


CMF C4 H4 O4

Double bond geometry as shown.




RN 329016-51-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[(cyclopropylmethyl)amino]ethoxy]-2-fluorophenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 329016-52-6 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[(cyclopropylmethyl)amino]ethoxy]-3-fluorophenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-53-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[(cyclopropylmethyl)amino]ethoxy]-3-fluorophenyl]-4,5,6,7-tetrahydro-4-oxo-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 329016-52-6


CMF C21 H24 F N3 O3



CM 2


CRN 104-15-4

CMF C7 H8 O3 S




RN 329016-54-8 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-[(2-methylpropyl)amino]ethoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-55-9 CAPLUS

CN 1H-Indole-3-carboxamide, N-[2-fluoro-4-[2-[(2-methylpropyl)amino]ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-56-0 CAPLUS

CN 1H-Indole-3-carboxamide, N-[3-fluoro-4-[2-[(2-methylpropyl)amino]ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-57-1 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-(butylamino)ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 329016-58-2 CAPLUS


CN 1H-Indole-3-carboxamide, N-[4-[2-(butylamino)ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329016-59-3 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-(butylamino)ethoxy]-3-fluorophenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-60-6 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[(1,1-dimethylethyl)amino]ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-61-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[(1,1-dimethylethyl)amino]ethoxy]-3-fluorophenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 329016-62-8 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(tricyclo[3.3.1.1.3,7]dec-2-ylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)



RN 329016-63-9 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[(2R)-2-pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 329016-64-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[(2S)-2-


pyrrolidinylmethoxy]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 329016-65-1 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-(3-piperidinylmethoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 329016-66-2 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-(3-piperidinylmethoxy)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 329016-67-3 CAPLUS


CN 1H-Indole-3-carboxamide, N-[4-[2-(dimethylamino)ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-68-4 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-[4-[2-(dimethylamino)ethoxy]-3-fluorophenyl]-  
 4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-69-5 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-70-8 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-[3-fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-  
 4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 329016-71-9 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-[3-fluoro-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-  
 4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-72-0 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(2-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329016-73-1 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[3-[(2,2,2-trifluoroethyl)amino]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329016-74-2 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[3-[(1-methylethyl)amino]propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-75-3 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[3-[(2-methylpropyl)amino]propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-76-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[3-[(cyclopropylmethyl)amino]propoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-76-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[3-[(cyclopropylmethyl)amino]propoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-77-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[3-(pentylamino)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329016-78-6 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[3-(cyclopentylamino)propoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-79-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[3-[(cyclopropylmethyl)propylamino]propoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-80-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-(methylamino)ethoxy]-3-pyridinyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329016-81-1 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-(ethylamino)ethoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 329016-82-2 CAPLUS


CN 1H-Indole-3-carboxamide, N-[4-[2-(ethylamino)ethoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329016-83-3 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(propylamino)ethoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 329016-84-4 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(propylamino)ethoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329016-85-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-[(1-methylethyl)amino]ethoxy]-3-pyridinyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 329016-86-6 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-[(1-methylethyl)amino]ethoxy]-3-pyridinyl]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329016-87-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-(butylamino)ethoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 329016-88-8 CAPLUS


CN 1H-Indole-3-carboxamide, N-[4-[2-(butylamino)ethoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329016-89-9 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[(1,1-dimethylethyl)amino]ethoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 329016-90-2 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-[(phenylmethyl)amino]ethoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 329016-91-3 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-


[(phenylmethyl)amino]ethoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329016-92-4 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-(3-pyridinylmethoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 329016-93-5 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-(3-pyridinylmethoxy)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329016-94-6 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-(4-pyridinylmethoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 329016-95-7 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-(4-pyridinylmethoxy)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 329016-96-8 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[(2R)-2-pyrrolidinylmethoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 329016-97-9 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[(2R)-2-pyrrolidinylmethoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 329016-98-0 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[(2S)-2-pyrrolidinylmethoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 329016-99-1 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-(dimethylamino)ethoxy]-3-pyridinyl]- 4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-00-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[3-(dimethylamino)propoxy]-3-pyridinyl]- 4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-01-8 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(1-pyrrolidinyl)ethoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 329017-02-9 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(1-pyrrolidinyl)ethoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329017-03-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-(4-methyl-1-piperazinyl)ethoxy]-3-pyridinyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-04-1 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-(4-morpholinyl)ethoxy]-3-pyridinyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-05-2 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(1-piperidinyl)ethoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 329017-06-3 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(1-piperidinyl)ethoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329017-07-4 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[(1-methyl-3-pyrrolidinyl)methoxy]-3-pyridinyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-08-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[(1-ethyl-3-pyrrolidinyl)methoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-09-6 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-3-pyridinyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 329017-10-9 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-3-pyridinyl]-4-oxo-, monohydrate (9CI) (CA INDEX NAME)



● H<sub>2</sub>O


RN 329017-11-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[3-(propylamino)propoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 329017-12-1 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[3-[(cyclopropylmethyl)amino]propoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-13-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[3-[(2-ethylbutyl)amino]propoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-14-3 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[3-(cyclohexylamino)propoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-15-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[3-[(cyclohexylmethyl)amino]propoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-16-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[3-[(4-pyridinylmethyl)amino]propoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 329017-17-6 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[3-(dipropylamino)propoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-18-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[3-[bis(cyclopropylmethyl)amino]propoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-19-8 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[3-[bis(2-ethylbutyl)amino]propoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-20-1 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[3-[bis(4-pyridinylmethyl)amino]propoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-21-2 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-[2-(1-pyrrolidinyl)ethoxy]ethoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 329017-22-3 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[[2,2-bis(methylamino)ethyl]amino]-2-oxoethyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-23-4 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-[4-(methylamino)-1-piperidinyl]-2-oxoethyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-24-5 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-(7-azabicyclo[2.2.1]hept-2-yloxy)phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-25-6 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[2-(diethylamino)ethoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-26-7 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[3-[2-(1-pyrrolidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329017-27-8 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[2-[bis(1-methylethyl)amino]ethoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-28-9 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[3-[2-(propylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329017-29-0 CAPLUS


CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[2-(butylamino)ethoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 329017-30-3 CAPLUS


CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[3-[3-(methylamino)propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)






RN 329017-31-4 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[3-(ethoxymethyl)propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-32-5 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[3-[(cyclopropylmethyl)propylamino]propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-33-6 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[3-(1-azetidinypropyl)propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-34-7 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[3-(ethylamino)propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-35-8 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[3-[3-[(2,2,2-trifluoroethyl)amino]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329017-36-9 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[3-[3-(propylamino)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329017-37-0 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[3-[3-[(1-methylethyl)amino]propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-38-1 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[3-(cyclopropylamino)propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-39-2 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[3-[(cyclopropylmethyl)amino]propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-40-5 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[3-(cyclobutylamino)propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-41-6 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[3-(cyclohexylamino)propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-42-7 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[3-[3-(pentylamino)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329017-43-8 CAPLUS


CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[3-[3-[(2-methylpropyl)amino]propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-44-9 CAPLUS  
 CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[3-[(1,1-dimethylethyl)amino]propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI)  
 (CA INDEX NAME)




RN 329017-45-0 CAPLUS  
 CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[3-[3-[(2-methylbutyl)amino]propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-46-1 CAPLUS  
 CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[3-[3-[(3-methylbutyl)amino]propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 329017-47-2 CAPLUS  
 CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[3-[3-[(4-methylpentyl)amino]propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-48-3 CAPLUS  
 CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[3-[(1,1-dimethylpropyl)amino]propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI)  
 (CA INDEX NAME)




RN 329017-49-4 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[3-[(3,3-dimethylbutyl)amino]propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI)  
(CA INDEX NAME)




RN 329017-50-7 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[3-[3-[(2-methyl-1-(1-methylethyl)propyl)amino]propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-51-8 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[3-[3-[(4-methylcyclohexyl)amino]propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-52-9 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[3-[(1,1-dimethylethyl)cyclohexyl]amino]propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-53-0 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[3-[(2,6-dimethylcyclohexyl)amino]propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo-(9CI) (CA INDEX NAME)




RN 329017-54-1 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[3-[3-[(1-phenylethyl)amino]propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329017-55-2 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[3-(bicyclo[2.2.1]hept-2-ylamino)propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-56-3 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[3-[3-(tricyclo[3.3.1.3^1,7]dec-1-ylamino)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329017-57-4 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[3-[3-[(bicyclo[2.2.1]hept-2-ylmethyl)amino]propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-58-5 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[3-[3-(tricyclo[3.3.1.1.3,7]dec-2-ylamino)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329017-59-6 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-[2-(ethylamino)ethoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 329017-60-9 CAPLUS


CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-[2-(ethylamino)ethoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329017-61-0 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-[2-(ethylamino)ethoxy]-2-fluorophenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-62-1 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[4-[2-(propylamino)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329017-63-2 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-[2-(cyclopropylamino)ethoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-64-3 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-[2-(butylamino)ethoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-65-4 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-[3-(ethylamino)propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-66-5 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[4-[3-[(1-methyl-1-phenylethyl)amino]propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-67-6 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[4-(3-pyridinylmethoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 329017-68-7 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[4-(4-pyridinylmethoxy)-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 329017-69-8 CAPLUS


CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[4-(4-pyridinylmethoxy)-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329017-70-1 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-[2-(dimethylamino)ethoxy]-3-pyridinyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-71-2 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-[2-(diethylamino)ethoxy]-3-pyridinyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-72-3 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[4-[2-(1-pyrrolidinyl)ethoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 329017-73-4 CAPLUS


CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[4-[2-(1-pyrrolidinyl)ethoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329017-74-5 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[4-[2-(1-piperidinyl)ethoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 329017-75-6 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[4-[2-(1-methyl-2-pyrrolidinyl)ethoxy]-3-pyridinyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-76-7 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-[(1-ethyl-3-pyrrolidinyl)methoxy]-3-pyridinyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-77-8 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[4-[2-(4-morpholinyl)ethoxy]-3-pyridinyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-78-9 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[4-[2-(propylamino)ethoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 329017-79-0 CAPLUS


CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[4-[2-(propylamino)ethoxy]-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 329017-80-3 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[4-[2-[(1-methylethyl)amino]ethoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-81-4 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[4-[3-[(1-methylethyl)amino]propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-82-5 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-[3-(cyclopropylamino)propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-83-6 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-[3-(cyclobutylamino)propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-84-7 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-[3-[(cyclopropylmethyl)amino]propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-85-8 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[4-[3-[(2-methylpropyl)amino]propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-86-9 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-[3-[(2,2-dimethylpropyl)amino]propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-87-0 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-4-oxo-N-[4-[3-(pentylamino)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329017-88-1 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[4-[3-[(2-methylbutyl)amino]propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-89-2 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[4-[3-[(3-methylbutyl)amino]propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-90-5 CAPLUS


CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-[3-(cyclohexylamino)propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 329017-91-6 CAPLUS


CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-[3-[(cyclopropylmethyl)propylamino]propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)






RN 329017-92-7 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-[4-[3-[(2,3-dihydro-1H-inden-2-yl)amino]propoxy]phenyl]-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-93-8 CAPLUS

CN Acetic acid, [2-fluoro-4-[[[(4,5,6,7-tetrahydro-4-oxo-1H-indol-3-yl)carbonyl]amino]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 329017-94-9 CAPLUS

CN Acetic acid, [2-fluoro-4-[[[(4,5,6,7-tetrahydro-4-oxo-1H-indol-3-yl)carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 329017-95-0 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-(ethylamino)-2-oxoethoxy]-3-fluorophenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-96-1 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-(diethylamino)-2-oxoethoxy]-3-fluorophenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-97-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-[3-fluoro-4-[2-(4-methyl-1-piperazinyl)-2-oxoethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-98-3 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[ethyl[2-(ethylamino)ethyl]amino]-2-oxoethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329017-99-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[[2-(dipropylamino)ethyl]amino]-2-oxoethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-00-0 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[[2-(diethylamino)ethyl]methylamino]-2-oxoethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-01-1 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[[2-(diethylamino)ethyl]ethylamino]-2-oxoethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-02-2 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-03-3 CAPLUS

CN 1H-Indole-3-carboxamide, N-[3-fluoro-4-[2-(4-morpholinyl)-2-oxoethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-04-4 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-oxo-2-(1-piperazinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329018-05-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[[3-(diethylamino)propyl]amino]-2-oxoethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-06-6 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[[3-(diethylamino)propyl]amino]-2-oxoethoxy]-3-fluorophenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-07-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[[4-(diethylamino)-1-methylbutyl]amino]-2-oxoethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-08-8 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[[4-(diethylamino)-1-methylbutyl]amino]-2-oxoethoxy]-3-phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-09-9 CAPLUS

CN 1H-Indole-3-carboxamide, N-[6-[2-(acetylmethylamino)ethyl]amino]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-10-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-(6-ethoxy-4-methyl-3-pyridinyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-11-3 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-[(2-thienylsulfonyl)amino]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 329018-13-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[3-[(1-methyl-1H-imidazol-4-yl)sulfonyl]amino]propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-20-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[ethyl(methylsulfonyl)amino]ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-21-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[3-(methylsulfonyl)propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-22-6 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[ethyl(ethylsulfonyl)amino]ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-23-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[ethyl(propylsulfonyl)amino]ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-24-8 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[ethyl(3-thienylsulfonyl)amino]ethoxy]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-25-9 CAPLUS

CN 1H-Indole-3-carboxamide, N-[6-[2-[ethyl(methylsulfonyl)amino]ethoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-26-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[6-[[1-(phenylmethyl)-1H-imidazol-2-yl]methoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 329018-27-1 CAPLUS

CN 1H-Indole-3-carboxamide, N-[2-(2-aminoethoxy)-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-28-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-[6-[2-[(ethylsulfonyl)amino]ethoxy]-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-29-3 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[6-[2-[(methylsulfonyl)amino]ethoxy]-3-pyridinyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-30-6 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-[(methylsulfonyl)amino]ethoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-31-7 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[2-[2-[(methylsulfonyl)amino]ethoxy]-3-pyridinyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-32-8 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[2-[2-[(2-thienylsulfonyl)amino]ethoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 329018-33-9 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[6-[(2-pyridinylmethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 329018-34-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[6-[(3-pyridinylmethyl)amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 329018-35-1 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-ethoxy-3-fluorophenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-36-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-[3-(2-ethoxyethoxy)phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-37-3 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-(1H-1,2,4-triazol-1-ylmethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 329018-38-4 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-[methyl(methylsulfonyl)amino]ethyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-39-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-  
[(methylsulfonyl)amino]ethyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 329018-40-8 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-  
[(methylsulfonyl)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




IT 329018-42-0P 329018-43-1P 329018-44-2P  
329018-45-3P 329018-46-4P 329018-47-5P  
329018-48-6P 329018-49-7P 329018-50-0P  
329018-51-1P 329018-53-3P 329018-54-4P  
329018-55-5P 329018-56-6P 329018-57-7P  
329018-58-8P 329018-59-9P 329018-60-2P  
329018-61-3P 329018-62-4P 329018-63-5P  
329018-64-6P 329018-65-7P 329018-66-8P  
329018-68-0P 329018-69-1P 329018-70-4P  
329018-71-5P 329018-72-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of fused pyrrolocarboxamides as GABA brain receptor ligands for treatment of central nervous system diseases)


RN 329018-42-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-  
(methylsulfonyl)ethyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-43-1 CAPLUS

CN Carbamic acid, [2-[4-[[4,5,6,7-tetrahydro-4-oxo-1H-indol-3-yl]carbonyl]amino]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 329018-44-2 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-(1H-imidazol-1-yl)ethyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-45-3 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-[(2-thienylsulfonyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329018-46-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[2-[(ethylsulfonyl)amino]ethyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-47-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[4-[2-(propylsulfonyl)amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)




RN 329018-48-6 CAPLUS

CN 1H-Indole-3-carboxamide, N-(5-ethoxy-2-pyridinyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-49-7 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[3-(methanesulfonyl)amino]propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-50-0 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-(3-aminopropoxy)phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-51-1 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-(5-propoxy-2-pyridinyl)- (9CI) (CA INDEX NAME)




RN 329018-53-3 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[6-[3-(4-pyridinyl)propoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 329018-54-4 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[6-[3-(3-pyridinyl)propoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 329018-55-5 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[6-[3-(2-pyridinyl)propoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)






RN 329018-56-6 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[6-[2-(2-pyridinyl)ethoxy]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 329018-57-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-[6-(ethylamino)-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-58-8 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[6-(methylamino)-3-pyridinyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-59-9 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[6-[[2-(1-pyrrolidinyl)ethyl]amino]-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 329018-60-2 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[6-(propylamino)-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 329018-61-3 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[6-[(2-methoxyethyl)amino]-3-pyridinyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-62-4 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-[6-(butylamino)-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 329018-63-5 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(6-ethoxy-3-pyridazinyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-64-6 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(6-methoxy-3-pyridazinyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-65-7 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-4-oxo-N-[6-(propylamino)-3-pyridazinyl]- (9CI) (CA INDEX NAME)




RN 329018-66-8 CAPLUS

CN 1H-Indole-3-carboxamide, N-[2-ethoxy-6-(ethylamino)-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-68-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[6-[(2-methylpropyl)amino]-3-pyridinyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-69-1 CAPLUS


CN 1H-Indole-3-carboxamide, N-[6-(acetylamino)-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 329018-70-4 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-[6-(acetylethylamino)-3-pyridinyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 329018-71-5 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[6-[[2-(4-morpholinyl)ethyl]amino]-3-pyridinyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 329018-72-6 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[3-(1H-imidazol-1-yl)propoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2002 ACS  
 AN 2000:814734 CAPLUS  
 DN 133:344635  
 TI Methods for screening GABA-modulatory compounds for cognitive-enhancing, anxiolytic, hypnotic, or antidepressant activities  
 IN Tallman, John; Gallager, Dorothy; Shaw, Kenneth; White, Geoffrey; Crandall, Marci; Cassella, James; Rajachandran, Lavanya; Albaugh, Pamela  
 PA Neurogen Corp., USA  
 SO PCT Int. Appl., 90 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000068691	A1	20001116	WO 2000-US12306	20000505
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,				

CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,  
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,  
SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1177445 A1 20020206 EP 2000-928860 20000505

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
IE, SI, LT, LV, FI, RO

BR 2000010344 A 20020219 BR 2000-10344 20000505

US 2002103108 A1 20020801 US 2001-45396 20011109

US 2002115611 A1 20020822 US 2001-45230 20011109

US 2002119911 A1 20020829 US 2001-45375 20011109

PRAI US 1999-133154P P 19990507

US 1999-133155P P 19990507

US 1999-133191P P 19990507

US 1999-133195P P 19990507

US 2000-565524 A3 20000505

WO 2000-US12306 W 20000505

AB Methods are provided that are useful in assaying compds. for  
cognitive-enhancing properties, anxiolytic properties, hypnotic  
properties, or antidepressant properties. The methods involve detg. the  
in vitro efficacy and EC50 of the compds. at defined series of cloned  
GABAA subtype receptors composed of specific variants of .alpha., .beta.,  
and .gamma. subunits in order to develop and an activity profile for each  
compd. Optionally, the binding affinities of the compds. at GABAA  
receptors are also detd. As an addnl. step the in vivo effects of the  
compds. may be tested in animal models.

IT 168271-95-2 168272-37-5 168272-49-9


194098-35-6 197300-15-5

RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES  
(Uses)

(GABA-modulatory compd. screening for cognitive-enhancing, anxiolytic,  
hypnotic, or antidepressant activity)


RN 168271-95-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-4-oxo-  
(9CI) (CA INDEX NAME)




RN 168272-37-5 CAPLUS


CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-methoxyphenyl)-4,5,6,7-tetrahydro-  
6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-49-9 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(2-hydroxyethoxy)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 194098-35-6 CAPLUS  
 CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[4-[(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 197300-15-5 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(4-fluorophenyl)-4,5,6,7-tetrahydro-6-methyl-4-oxo- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2002 ACS

AN 1999:350648 CAPLUS

DN 130:352183

TI Method of synthesis of pyrrole amides

IN Ragan, John Anthony; Makowski, Teresa Woodall; Am Ende, David Jon; Clifford, Pamela Jane; Young, Gregory Randall; Conrad, Alyson Kay; Eisenbeis, Shane Allen; Quallich, George Joseph; Allen, Douglas John Meldrum

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 31 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9925684	A1	19990527	WO 1998-IB1672	19981021
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,				

KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,  
 MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,  
 TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2310095 AA 19990527 CA 1998-2310095 19981021  
 AU 9893639 A1 19990607 AU 1998-93639 19981021  
 AU 745788 B2 20020328  
 EP 1030838 A1 20000830 EP 1998-946678 19981021

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,  
 SI, LT, LV, FI, RO

BR 9814161 A 20000926 BR 1998-14161 19981021  
 JP 2001523660 T2 20011127 JP 2000-521068 19981021  
 ZA 9810350 A 20000512 ZA 1998-10350 19981112  
 US 6262272 B1 20010717 US 1999-403985 19990119  
 NO 2000002214 A 20000512 NO 2000-2214 20000428

PRAI US 1997-65422P P 19971113  
 US 1998-74266P P 19980210  
 WO 1998-IB1672 W 19981021


AB A method for prepg. pyrrolicarboxamides which selectively bind to GABA<sub>A</sub>  
 receptors; which comprises reacting 1,3-cycloalkanediones with  
 bromopyruvate followed by reaction of the resulting product with an acid  
 halide followed by reaction with an arom. amine and finally with an  
 ammonium source at an elevated temp.

IT 225240-85-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (prepn. of pyrrolicarboxamides)

RN 225240-85-7 CAPLUS

CN Carbamic acid, methyl[[4-[[[4,5,6,7-tetrahydro-4-oxo-1H-indol-3-  
 yl]carbonyl]amino]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA  
 INDEX NAME)




IT 168271-93-0P 168272-37-5P 168272-59-1P  
 194098-25-4P 194098-59-4P 197300-15-5P  
 225240-86-8P 225240-89-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. of pyrrolicarboxamides)


RN 168271-93-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-methoxyphenyl)-4-oxo-  
 (9CI) (CA INDEX NAME)




RN 168272-37-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-methoxyphenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-59-1 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-(2-fluoro-4-methoxyphenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-25-4 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-59-4 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[6-(2-hydroxyethoxy)-3-pyridinyl]-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-15-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-fluorophenyl)-4,5,6,7-tetrahydro-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 225240-86-8 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[(methylamino)methyl]phenyl]-4-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 225240-89-1 CAPLUS  
 CN Cyclopenta[b]pyrrole-3-carboxamide, N-(4-ethoxyphenyl)-1,4,5,6-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2002 ACS  
 AN 1998:306978 CAPLUS  
 DN 129:4586  
 TI Preparation of certain pyrrolopyridine-3-carboxamides as a new class of GABA brain receptor ligands  
 IN Albaugh, Pamela; Hutchison, Alan  
 PA Neurogen Corporation, USA  
 SO U.S., 23 pp., Cont.-in-part of U.S. 5,608,079.  
 CODEN: USXXAM

DT Patent  
 LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5750702	A	19980512	US 1996-683066	19960716
	US 5484944	A	19960116	US 1993-144138	19931027
	EP 825193	A1	19980225	EP 1997-117241	19941026
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
	US 5608079	A	19970304	US 1995-473509	19950607
	WO 9802433	A1	19980122	WO 1997-US7830	19970509
	W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,				

ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS,  
 LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,  
 SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM  
 RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,  
 GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,  
 ML, MR, NE, SN, TD, TG  
 AU 9728328 A1 19980209 AU 1997-28328 19970509  
 WO 9802420 A1 19980122 WO 1997-US12153 19970714  
 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,  
 DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,  
 RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN,  
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,  
 GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,  
 GN, ML, MR, NE, SN, TD, TG  
 AU 9736604 A1 19980209 AU 1997-36604 19970714  
 ZA 9706244 A 19990121 ZA 1997-6244 19970715  
 US 5925770 A 19990720 US 1998-73030 19980505  
 AU 9923799 A1 19990603 AU 1999-23799 19990416  
 AU 729634 B2 20010208  
 PRAI US 1993-144138 A1 19931027  
 US 1995-473509 A2 19950607  
 AU 1994-81265 A3 19941026  
 EP 1995-900440 A3 19941026  
 US 1996-683066 A2 19960716  
 WO 1997-US7830 W 19970509  
 WO 1997-US12153 W 19970714  
 OS  
 GI MARPAT 129:4586

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. [I; W = (un)substituted Ph; X = H, OH, lower alkyl; T = halo, H, OH, etc.; ring C = II-V (wherein R3 = H, Ph, pyridyl, etc.; R4 = halo, CF3, OH, etc.; R5, R6 = H, halo, lower alkyl, lower alkoxy; R7 = H, Ph, pyridyl, etc.; n = 1-4)] which are highly selective agonists, antagonists or inverse agonists for GABA<sub>A</sub> brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA<sub>A</sub> brain receptors and therefore useful in the diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory, were prepd. Thus, reaction of 4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid and p-anisidine in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) in 50% aq. 1,4-dioxane afforded the title compd. VI which showed K<sub>i</sub> of 4 nM against GABA<sub>A</sub> receptor binding.


IT 168271-95-2P 202202-66-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of certain pyrrolopyridine-3-carboxamides as a new class of GABA brain receptor ligands)


RN 168271-95-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-4-oxo-(9CI) (CA INDEX NAME)



RN 202202-66-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-2-nitro-4-oxo- (9CI) (CA INDEX NAME)




IT 168271-93-0P 168272-02-4P 168272-03-5P  
 168272-05-7P 168272-10-4P 168272-13-7P  
 168272-15-9P 168272-17-1P 168272-18-2P  
 168272-26-2P 168272-28-4P 168272-36-4P  
 168272-41-1P 168272-44-4P 168272-46-6P  
 168272-47-7P 168272-54-6P 168272-59-1P  
 168272-60-4P 168272-61-5P 202202-67-3P  
 202202-74-2P 202202-84-4P 202203-12-1P  
 202203-18-7P 202203-39-2P 202203-88-1P  
 202204-52-2P 202204-70-4P 202205-04-7P  
 202205-28-5P 202205-42-3P 202206-10-8P  
 202206-11-9P 202206-12-0P 202206-38-0P  
 202206-85-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of certain pyrrolopyridine-3-carboxamides as a new class of GABA brain receptor ligands)


RN 168271-93-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-02-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-cyanophenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-03-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(3-methoxyphenyl)-4-oxo-  
(9CI) (CA INDEX NAME)




RN 168272-05-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-chlorophenyl)-4,5,6,7-tetrahydro-4-oxo-  
(9CI) (CA INDEX NAME)




RN 168272-10-4 CAPLUS


CN Benzoic acid, 4-[[[(4,5,6,7-tetrahydro-4-oxo-1H-indol-3-yl) carbonyl] amino]-  
, methyl ester (9CI) (CA INDEX NAME)




RN 168272-13-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-(3-ethoxyphenyl)-4,5,6,7-tetrahydro-4-oxo-  
(9CI) (CA INDEX NAME)







RN 168272-15-9 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(4-fluorophenyl)-4,5,6,7-tetrahydro-4-oxo-  
 (9CI) (CA INDEX NAME)




RN 168272-17-1 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-hydroxyphenyl)-4-oxo-  
 (9CI) (CA INDEX NAME)



RN 168272-18-2 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(4-aminophenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI)  
 (CA INDEX NAME)




RN 168272-26-2 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-[2-fluoro-4-(1-methylethoxy)phenyl]-4,5,6,7-  
 tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-28-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-methoxyphenyl)-4,5,6,7-tetrahydro-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-36-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-hydroxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-41-1 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-44-4 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(methylamino)phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-46-6 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(3-hydroxy-4-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-47-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluorophenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-54-6 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-(4-ethoxyphenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-59-1 CAPLUS


CN Cyclohepta[b]pyrrole-3-carboxamide, N-(2-fluoro-4-methoxyphenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 168272-60-4 CAPLUS


CN Cyclohepta[b]pyrrole-3-carboxamide, N-(4-ethoxy-2-fluorophenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)






RN 168272-61-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-fluoro-2-hydroxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202202-67-3 CAPLUS

CN 1H-Indole-3-carboxamide, 2-amino-N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202202-74-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-(3-fluorophenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202202-84-4 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(2-hydroxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 202203-12-1 CAPLUS  
CN 1H-Indole-3-carboxamide, N-(2-fluoro-5-methylphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202203-18-7 CAPLUS  
CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-methylphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202203-39-2 CAPLUS  
CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(2-hydroxy-4-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 202203-88-1 CAPLUS  
CN 1H-Indole-3-carboxamide, N-(4-chloro-2-hydroxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202204-52-2 CAPLUS  
CN 1H-Indole-3-carboxamide, N-(2-fluorophenyl)-4,5,6,7-tetrahydro-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 202204-70-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-(3-fluorophenyl)-4,5,6,7-tetrahydro-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 202205-04-7 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-hydroxyphenyl)-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 202205-28-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-hydroxyphenyl)-4,5,6,7-tetrahydro-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 202205-42-3 CAPLUS


CN 1H-Indole-3-carboxamide, N-(4-ethoxy-2-fluorophenyl)-4,5,6,7-tetrahydro-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 202206-10-8 CAPLUS  
CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-(3-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 202206-11-9 CAPLUS  
CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-(4-hydroxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 202206-12-0 CAPLUS  
CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-(4-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 202206-38-0 CAPLUS  
CN Cyclohepta[b]pyrrole-3-carboxamide, N-(2-fluoro-4-hydroxyphenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 202206-85-7 CAPLUS  
CN 1H-Indole-3-carboxamide, N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-2-methyl-4-oxo- (9CI) (CA INDEX NAME)




IT 168271-98-5 168272-04-6 168272-08-0  
168272-14-8 168272-55-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(prepn. of certain pyrrolopyridine-3-carboxamides as a new class of GABA brain receptor ligands)


RN 168271-98-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-methoxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-04-6 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-(acetylamino)phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-08-0 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-5-methoxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-14-8 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(1-methylethoxy)phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 168272-55-7 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-(2-fluorophenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)



RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2002 ACS

AN 1998:157416 CAPLUS

DN 128:204804

TI Preparation of certain fused pyrrolocarboxamides as a new class of GABA brain receptor ligands

IN Albaugh, Pamela; Liu, Gang; Hutchison, Alan

PA Neurogen Corp., USA

SO U.S., 19 pp.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5723462	A	19980303	US 1996-639166	19960426
	US 6096887	A	20000801	US 1998-31315	19980225
PRAI	US 1996-639166	A1	19960426		
OS	MARPAT 128:204804				
GI					



AB The title compds. [I; W = (un)substituted thiazolyl, quinoxalinyll; X = H, OH, lower alkyl; T = H, halo, OH, etc.; R8 = H, C1-6 alkyl; R9 = H, Ph, pyridyl, etc.], highly selective agonists, antagonists or inverse agonists for GABA<sub>A</sub> brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA<sub>A</sub> brain receptor and therefore useful in the diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with

benzodiazepine drugs and for enhancement of memory, were prepd. Thus, reaction of 4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid with 2-methoxy-5-aminopyridine afforded I [X = H; T = H; W = 2-methoxy-5-pyridyl; R8 = R9 = H] which showed Ki of 11 nM against GABAa receptor binding.


IT 168272-32-0P 168272-56-8P 202212-12-2P  
202212-19-9P 202212-25-7P 202213-70-5P  
203937-48-8P 203937-49-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of certain fused pyrrolicarboxamides as a new class of GABA brain receptor ligands)


RN 168272-32-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(6-methoxy-3-pyridinyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-56-8 CAPLUS

CN 1H-Indole-3-carboxamide, N-(7-chloro-1,8-naphthyridin-2-yl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202212-12-2 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(7-methoxy-1,8-naphthyridin-2-yl)-4-oxo- (9CI) (CA INDEX NAME)




RN 202212-19-9 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(5-methyl-2-thiazolyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 202212-25-7 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(6-methyl-1,8-naphthyridin-2-yl)-4-oxo- (9CI) (CA INDEX NAME)




RN 202213-70-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-(5,7-dimethyl-1,8-naphthyridin-2-yl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 203937-48-8 CAPLUS

CN 1H-Indole-3-carboxamide, N-(6-ethoxy-3-pyridinyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)









RN 203937-49-9 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-(6-methoxy-3-pyridinyl)-4-oxo- (9CI) (CA INDEX NAME)



L8 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2002 ACS  
 AN 1998:71132 CAPLUS  
 DN 128:140608  
 TI Preparation of fused pyrrolocarboxamides as a new class of GABA brain receptor ligands  
 IN Albaugh, Pamela; Liu, Gang; Hutchison, Alan  
 PA Neurogen Corporation, USA; Albaugh, Pamela; Liu, Gang; Hutchison, Alan  
 SO PCT Int. Appl., 58 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9802433	A1	19980122	WO 1997-US7830	19970509
	W:	AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 5750702	A	19980512	US 1996-683066	19960716
	AU 9728328	A1	19980209	AU 1997-28328	19970509
	AU 9923799	A1	19990603	AU 1999-23799	19990416
	AU 729634	B2	20010208		
PRAI	US 1996-683066	A2	19960716		
	US 1993-144138	A1	19931027		
	AU 1994-81265	A3	19941026		
	US 1995-473509	A2	19950607		
	WO 1997-US7830	W	19970509		
OS	MARPAT 128:140608				
GI					



AB The title compds. [I; T = H, OH, NO<sub>2</sub>, etc.; X = H, OH, C1-6 alkyl; W =

(un)substituted heteroaryl; ring C = II, III, IV, V (wherein Y = CR<sup>4</sup>, N; Z = NR<sup>7</sup>, CR<sup>8</sup>R<sup>9</sup>; n = 1-4; R<sup>3</sup> = H, Ph, pyridyl, etc.; R<sup>4</sup> = G, halo, CF<sub>3</sub>, etc.; R<sup>5</sup>, R<sup>6</sup> = H, halo, C1-6 alkyl, C1-6 alkoxy; R<sup>7</sup> = H, Ph, pyridyl, etc.; R<sup>8</sup> = H, C1-6 alkyl; R<sup>9</sup> = H, Ph, pyridyl, etc.)), highly selective agonists, antagonists or inverse agonists for GABA<sub>A</sub> brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA<sub>A</sub> brain receptors, were prepd. Comps. I are useful in the diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Thus, treatment of 4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid with ClCO<sub>2</sub>Et in the presence of Et<sub>3</sub>N in DMF followed by addn. of 2-methoxy-5-aminopyridine in DMF afforded the title compd. VI which showed K<sub>i</sub> of 11 nM against GABA<sub>A</sub> receptor binding.


IT 168272-32-0P 168272-56-8P 202212-12-2P  
202212-19-9P 202212-25-7P 202213-10-3P  
202213-69-2P 202213-70-5P 202213-81-8P  
202213-82-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of fused pyrrolocarboxamides as a new class of GABA brain receptor ligands)


RN 168272-32-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(6-methoxy-3-pyridinyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-56-8 CAPLUS

CN 1H-Indole-3-carboxamide, N-(7-chloro-1,8-naphthyridin-2-yl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202212-12-2 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(7-methoxy-1,8-naphthyridin-2-yl)-4-oxo- (9CI) (CA INDEX NAME)




RN 202212-19-9 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(5-methyl-2-thiazolyl)-4-oxo-  
(9CI) (CA INDEX NAME)




RN 202212-25-7 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(6-methyl-1,8-naphthyridin-2-yl)-4-oxo- (9CI) (CA INDEX NAME)




RN 202213-10-3 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-ethoxy-3-pyridinyl)-4,5,6,7-tetrahydro-4-oxo-  
(9CI) (CA INDEX NAME)




RN 202213-69-2 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-(4-methoxy-3-pyridinyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 202213-70-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-(5,7-dimethyl-1,8-naphthyridin-2-yl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202213-81-8 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-methoxy-3-pyridinyl)-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)



RN 202213-82-9 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-methyl-3-pyridinyl)-4-oxo- (9CI) (CA INDEX NAME)



L8 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2002 ACS

AN 1998:66173 CAPLUS

DN 128:140607

TI Preparation of fused pyrrolocarboxanilides as a new class of GABA brain receptor ligands

IN Albaugh, Pamela; Hutchison, Alan; Liu, Gang

PA Hutchison, Alan, USA; Liu, Gang; Neurogen Corporation; Albaugh, Pamela

SO PCT Int. Appl., 86 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9802420	A1	19980122	WO 1997-US12153	19970714
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5750702	A	19980512	US 1996-683066	19960716
	AU 9736604	A1	19980209	AU 1997-36604	19970714
	AU 9923799	A1	19990603	AU 1999-23799	19990416

AU 729634	B2	20010208
PRAI US 1996-683066	A2	19960716
US 1993-144138	A1	19931027
AU 1994-81265	A3	19941026
US 1995-473509	A2	19950607
WO 1997-US12153	W	19970714
OS MARPAT 128:140607		
GI		



AB The title compds. [I; T = H, halo, OH, etc.; X = H, OH, lower alkyl; W = (un)substituted Ph; ring C = II, III, IV, V; (wherein Y = N, CR<sub>4</sub>; Z = NR<sub>7</sub>, CR<sub>8</sub>R<sub>9</sub>; n = 1-4; R<sub>3</sub> = H, Ph, pyridyl, etc.; R<sub>4</sub> = halo, CF<sub>3</sub>, OH, etc.; R<sub>5</sub>, R<sub>6</sub> = H, halo, lower alkyl, lower alkoxy; R<sub>7</sub> = H, Ph, pyridyl, etc.; R<sub>8</sub> = H, lower alkyl; R<sub>9</sub> = CONR<sub>14</sub>R<sub>15</sub>; R<sub>14</sub> = H, lower alkyl; R<sub>15</sub> = H, Ph, pyridyl, etc.; NR<sub>14</sub>R<sub>15</sub> = morpholino, piperidino, pyrrolidino, N-alkylpiperazino)], highly selective agonists, antagonists or inverse agonists for GABA<sub>A</sub> brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA<sub>A</sub> brain receptors which are useful in the diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory, were prepd. Thus, reaction of 4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid with p-anisidine in the presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide.HCl in 50% aq. 1,4-dioxane afforded the title compd. VI which showed K<sub>i</sub> of 4 nM against GABA<sub>2</sub> receptor binding.


IT 168271-95-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of fused pyrrolocarboxanilides as a new class of GABA brain receptor ligands)

RN 168271-95-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-4-oxo-(9CI) (CA INDEX NAME)




IT 168271-93-0P 168272-02-4P 168272-03-5P  
 168272-04-6P 168272-10-4P 168272-13-7P  
 168272-15-9P 168272-17-1P 168272-18-2P  
 168272-21-7P 168272-26-2P 168272-27-3P  
 168272-28-4P 168272-29-5P 168272-31-9P  
 168272-33-1P 168272-36-4P 168272-37-5P  
 168272-38-6P 168272-39-7P 168272-41-1P  
 168272-42-2P 168272-43-3P 168272-44-4P  
 168272-46-6P 168272-47-7P 168272-48-8P  
 168272-54-6P 168272-55-7P 168272-59-1P  
 168272-60-4P 168272-61-5P 202202-66-2P  
 202202-67-3P 202202-74-2P 202202-84-4P  
 202203-12-1P 202203-18-7P 202203-39-2P  
 202203-88-1P 202204-52-2P 202204-70-4P  
 202204-84-0P 202205-04-7P 202205-28-5P  
 202205-42-3P 202206-10-8P 202206-11-9P  
 202206-12-0P 202206-38-0P 202206-85-7P  
 202207-33-8P 202208-60-4P 202208-88-6P  
 202208-92-2P 202208-96-6P 202209-05-0P  
 202209-26-5P 202209-27-6P 202209-28-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Préparation); USES (Uses)  
 (prepn. of fused pyrrolocarboxanilides as a new class of GABA brain receptor ligands)


RN 168271-93-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 168272-02-4 CAPLUS


CN 1H-Indole-3-carboxamide, N-(4-cyanophenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 168272-03-5 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(3-methoxyphenyl)-4-oxo-

(9CI) (CA INDEX NAME)




RN 168272-04-6 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-(acetylamino)phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-10-4 CAPLUS

CN Benzoic acid, 4-[[[(4,5,6,7-tetrahydro-4-oxo-1H-indol-3-yl)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 168272-13-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-(3-ethoxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-15-9 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-fluorophenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-17-1 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-hydroxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-18-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-aminophenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-21-7 CAPLUS


CN 1H-Indole-3-carboxamide, N-(3-fluoro-4-methoxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 168272-26-2 CAPLUS


CN 1H-Indole-3-carboxamide, N-[2-fluoro-4-(1-methylethoxy)phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)






RN 168272-27-3 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-fluorophenyl)-4,5,6,7-tetrahydro-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-28-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-methoxyphenyl)-4,5,6,7-tetrahydro-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-29-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-31-9 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-methoxyphenyl)-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-33-1 CAPLUS  
CN 1H-Indole-3-carboxamide, N-(3,4-dihydroxyphenyl)-4,5,6,7-tetrahydro-4-oxo-  
(9CI) (CA INDEX NAME)




RN 168272-36-4 CAPLUS  
CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-hydroxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-37-5 CAPLUS  
CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-methoxyphenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-38-6 CAPLUS  
CN 1H-Indole-3-carboxamide, N-(4-ethoxy-2-fluorophenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-39-7 CAPLUS  
CN 1H-Indole-3-carboxamide, N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-41-1 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-methylphenyl)-4-oxo-  
 (9CI) (CA INDEX NAME)




RN 168272-42-2 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(3-methylphenyl)-4-oxo-  
 (9CI) (CA INDEX NAME)



RN 168272-43-3 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(2-amino-4-methylphenyl)-4,5,6,7-tetrahydro-4-oxo-  
 (9CI) (CA INDEX NAME)




RN 168272-44-4 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(methylamino)phenyl]-4-oxo-  
 (9CI) (CA INDEX NAME)




RN 168272-46-6 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(3-hydroxy-4-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-47-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluorophenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-48-8 CAPLUS

CN 1H-Indole-3-carboxamide, N-(3-fluorophenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-54-6 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-(4-ethoxyphenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-55-7 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-(2-fluorophenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-59-1 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-(2-fluoro-4-methoxyphenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-60-4 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-(4-ethoxy-2-fluorophenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-61-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-fluoro-2-hydroxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202202-66-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-2-nitro-4-oxo- (9CI) (CA INDEX NAME)




RN 202202-67-3 CAPLUS

CN 1H-Indole-3-carboxamide, 2-amino-N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202202-74-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-(3-fluorophenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202202-84-4 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(2-hydroxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 202203-12-1 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-5-methylphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202203-18-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-methylphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202203-39-2 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(2-hydroxy-4-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 202203-88-1 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-chloro-2-hydroxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202204-52-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluorophenyl)-4,5,6,7-tetrahydro-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 202204-70-4 CAPLUS


CN 1H-Indole-3-carboxamide, N-(3-fluorophenyl)-4,5,6,7-tetrahydro-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 202204-84-0 CAPLUS  
CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-5,5-dimethyl-N-(3-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 202205-04-7 CAPLUS  
CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-hydroxyphenyl)-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 202205-28-5 CAPLUS  
CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-hydroxyphenyl)-4,5,6,7-tetrahydro-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)



RN 202205-42-3 CAPLUS  
CN 1H-Indole-3-carboxamide, N-(4-ethoxy-2-fluorophenyl)-4,5,6,7-tetrahydro-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 202206-10-8 CAPLUS  
CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-(3-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 202206-11-9 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-(4-hydroxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 202206-12-0 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-(4-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 202206-38-0 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-(2-fluoro-4-hydroxyphenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202206-85-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-2-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 202207-33-8 CAPLUS

CN 1H-Indole-3-carboxamide, N-(5-bromo-2-methoxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202208-60-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-(3-chlorophenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202208-88-6 CAPLUS

CN 1H-Indole-3-carboxamide, 2-bromo-N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202208-92-2 CAPLUS

CN 1H-Indole-3-carboxamide, 2-chloro-N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202208-96-6 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(3-methoxyphenyl)-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 202209-05-0 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-5-methoxyphenyl)-4,5,6,7-tetrahydro-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 202209-26-5 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-(3-fluorophenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202209-27-6 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-(4-fluorophenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 202209-28-7 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-(2-fluoro-5-methoxyphenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)



L8 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2002 ACS  
 AN 1997:640642 CAPLUS  
 DN 127:307298  
 TI Preparation of fused pyrrolocarboxamides as GABA brain receptor ligands  
 IN Albaugh, Pamela; Liu, Gang; Hutchison, Alan  
 PA Neurogen Corp., USA; Albaugh, Pamela; Liu, Gang; Hutchison, Alan  
 SO PCT Int. Appl., 46 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9734870	A1	19970925	WO 1997-US4623	19970320
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2249562	AA	19970925	CA 1997-2249562	19970320
	AU 9722189	A1	19971010	AU 1997-22189	19970320
	EP 888300	A1	19990107	EP 1997-915182	19970320
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	US 2001020035	A1	20010906	US 1998-88522	19980601
	US 6353109	B2	20020305		
PRAI	US 1996-620939	A2	19960322		
	WO 1997-US4623	W	19970320		
OS	MARPAT 127:307298				
GI					



AB The title compds. [I; W = (un)substituted Ph; T = H, halo, OH, NH<sub>2</sub>, alkyl; X = H, OH, lower alkyl; m = 0-2; n = 0-2; R<sub>3</sub>, R<sub>4</sub> = H, alkyl, COalkyl, etc.; R<sub>3</sub>R<sub>4</sub> = C<sub>3</sub>-7 cyclic moiety], highly selective agonists, antagonists or inverse agonists for GABA<sub>A</sub> brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA<sub>A</sub> brain receptors and therefore useful in the diagnosis and treatment of anxiety, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of


memory, were prepd. Thus, treatment of 4-oxo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid with ClCOOEt and Et3N in DMF followed by addn. of 2-fluoroaniline afforded I [W = 2-pyridyl; T = X = H; m = n = 1; R3 = R4 = Me] which showed Ki of 12 nM against GABAA receptor binding.

IT 168272-37-5P 168272-38-6P 168272-39-7P  
 168272-48-8P 197300-08-6P 197300-09-7P  
 197300-10-0P 197300-11-1P 197300-13-3P  
 197300-14-4P 197300-15-5P 197300-16-6P  
 197300-17-7P 197300-18-8P 197300-19-9P  
 197300-20-2P 197300-21-3P 197300-22-4P  
 197300-23-5P 197300-24-6P 197300-25-7P  
 197300-27-9P 197300-28-0P 197300-32-6P  
 197300-34-8P 197300-35-9P 197300-36-0P  
 197300-37-1P 197300-38-2P 197300-39-3P  
 197300-40-6P 197300-43-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of fused pyrrolocarboxamides as GABA brain receptor ligands)


RN 168272-37-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-methoxyphenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-38-6 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-ethoxy-2-fluorophenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)



RN 168272-39-7 CAPLUS


CN 1H-Indole-3-carboxamide, N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)



RN 168272-48-8 CAPLUS


CN 1H-Indole-3-carboxamide, N-(3-fluorophenyl)-4,5,6,7-tetrahydro-6,6-

dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-08-6 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluorophenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-09-7 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(2-hydroxy-4-methoxyphenyl)-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-10-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(3-hydroxy-4-methoxyphenyl)-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-11-1 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(2-hydroxy-4-methylphenyl)-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-13-3 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(2-fluorophenyl)-4,5,6,7-tetrahydro-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-14-4 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(3-fluorophenyl)-4,5,6,7-tetrahydro-6-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 197300-15-5 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(4-fluorophenyl)-4,5,6,7-tetrahydro-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-16-6 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(3-methoxyphenyl)-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-17-7 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-hydroxyphenyl)-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-18-8 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-hydroxyphenyl)-4,5,6,7-tetrahydro-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-19-9 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(2-hydroxy-4-methoxyphenyl)-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-20-2 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-methoxyphenyl)-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-21-3 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-methoxyphenyl)-4,5,6,7-tetrahydro-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-22-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-23-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-ethoxy-2-fluorophenyl)-4,5,6,7-tetrahydro-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-24-6 CAPLUS


CN 1H-Indole-3-carboxamide, N-(3,4-dihydroxyphenyl)-4,5,6,7-tetrahydro-6-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 197300-25-7 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(2-hydroxy-4-methylphenyl)-6-methyl-4-oxo- (9CI) (CA INDEX NAME)






RN 197300-27-9 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-methoxy-3-pyridinyl)-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-28-0 CAPLUS

CN 1H-Indole-3-carboxamide, N-(7-chloro-1,8-naphthyridin-2-yl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-32-6 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-6-methyl-N-(6-methyl-1,8-naphthyridin-2-yl)-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-34-8 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-fluorophenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-35-9 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2,6-difluorophenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-36-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(3-methoxyphenyl)-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-37-1 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-5-methoxyphenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-38-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-hydroxyphenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-39-3 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-methoxyphenyl)-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 197300-40-6 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-6,6-dimethyl-N-(4-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 197300-43-9 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-6,6-dimethyl-N-(5-methyl-2-thiazolyl)-4-oxo- (9CI) (CA INDEX NAME)



L8 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2002 ACS

AN 1997:499171 CAPLUS

DN 127:190644

TI Preparation of fused pyrrolocarboxamides as GABA brain receptor ligands.

IN Albaugh, Pamela; Liu, Gang; Shaw, Kenneth; Hutchison, Alan

PA Neurogen Corp., USA; Albaugh, Pamela; Liu, Gang; Shaw, Kenneth; Hutchison, Alan

SO PCT Int. Appl., 51 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9726243	A1	19970724	WO 1997-US519	19970114
	W:		AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
	US 5804686	A	19980908	US 1996-588711	19960119
	CA 2243317	AA	19970724	CA 1997-2243317	19970114
	AU 9717466	A1	19970811	AU 1997-17466	19970114

CN 1209805	A	19990303	CN 1997-191759	19970114
BR 9707051	A	19990720	BR 1997-7051	19970114
JP 2000503321	T2	20000321	JP 1997-526110	19970114
EP 1019372	A1	20000719	EP 1997-904754	19970114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
RU 2167151	C2	20010520	RU 1998-115534	19970114
ZA 9708292	A	19980525	ZA 1997-8292	19970915
NO 9803315	A	19980903	NO 1998-3315	19980717
PRAI US 1996-588711	A1	19960119		
WO 1997-US519	W	19970114		
OS MARPAT 127:190644				
GI				




AB Title compds. [I; G = Q(CH<sub>2</sub>)<sub>k</sub>W(CH<sub>2</sub>)<sub>m</sub>Z; Q = Ph, thienyl, pyridyl optionally mono- or disubstituted with OH or halo; T = H, halo, OH, amino alkoxy; W = O, N, S, (substituted) methylene; X = H, OH, alkyl; Z = OH, alkoxy, cycloalkylalkoxy, amino, acylamino, atoms to form a 1-ring with Q; A = (CH<sub>2</sub>)<sub>n</sub>; n = 0-3; R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> = H, alkyl, COR<sub>11</sub>, CO<sub>2</sub>R<sub>11</sub>, CONR<sub>12</sub>R<sub>13</sub>; R<sub>11</sub> = alkyl, cycloalkyl; R<sub>12</sub>, R<sub>13</sub> = H, alkyl, cycloalkyl, PH, pyridyl; NR<sub>12</sub>R<sub>13</sub> = morpholinyl, piperidinyl, pyrrolidinyl, alkylpiperazinyl], were prepd. Thus, 4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxylic acid (prepn. given) and Et<sub>3</sub>N in DMF were treated with EtO<sub>2</sub>CCl and then with 3-[(N-trifluoroacetyl)methylaminomethyl]aniline (prepn. given) to give N-[3-(methylaminomethyl)phenyl]-4-oxo-4,5,6,7-tetrahydro-1H-indole-3-carboxamide. I showed GABA<sub>A</sub> receptor binding activity with K<sub>i</sub> = 0.24-90 nM.

IT 168272-20-6P 168272-25-1P 168272-30-8P  
168272-49-9P 168272-51-3P 194098-24-3P  
194098-25-4P 194098-26-5P 194098-27-6P  
194098-28-7P 194098-29-8P 194098-30-1P  
194098-31-2P 194098-32-3P 194098-33-4P  
194098-34-5P 194098-35-6P 194098-36-7P  
194098-37-8P 194098-38-9P 194098-39-0P  
194098-40-3P 194098-41-4P 194098-42-5P  
194098-43-6P 194098-44-7P 194098-53-8P  
194098-59-4P 194098-92-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of fused pyrrolicarboxamides as GABA brain receptor ligands)


RN 168272-20-6 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(methoxymethyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-25-1 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2,2-dimethyl-1,3-benzodioxol-5-yl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-30-8 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(methoxymethyl)phenyl]-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-49-9 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(2-hydroxyethoxy)phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-51-3 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(2-methoxyethoxy)phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-24-3 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[3-[(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-25-4 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-26-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-(aminomethyl)phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-27-6 CAPLUS

CN 1H-Indole-3-carboxamide, N-[2-fluoro-4-[(methylamino)methyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-28-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[(acetylmethylamino)methyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-29-8 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-[(ethylamino)methyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-30-1 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[[1-methylethyl)amino]methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-31-2 CAPLUS


CN 1H-Indole-3-carboxamide, N-[4-[(cyclopropylamino)methyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 194098-32-3 CAPLUS


CN 1H-Indole-3-carboxamide, N-[4-[(dimethylamino)methyl]phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)






RN 194098-33-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-(2-aminoethyl)phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-34-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-(methylamino)ethyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-35-6 CAPLUS


CN Cyclohepta[b]pyrrole-3-carboxamide, 1,4,5,6,7,8-hexahydro-N-[4-[(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 194098-36-7 CAPLUS


CN 1H-Indole-3-carboxamide, N-[4-[(acetylmethylamino)methyl]phenyl]-4,5,6,7-tetrahydro-6-methyl-4-oxo- (9CI) (CA INDEX NAME)






RN 194098-37-8 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-6-methyl-N-[4-((methylamino)methyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-38-9 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(hydroxymethyl)phenyl]-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-39-0 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(2-hydroxyethoxy)phenyl]-6-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 194098-40-3 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-6-methyl-N-[3-((methylamino)methyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)






RN 194098-41-4 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(2-hydroxyethoxy)phenyl]-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-42-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[3-(hydroxymethyl)phenyl]-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-43-6 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(hydroxymethyl)phenyl]-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-44-7 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-6,6-dimethyl-N-[4-[(methylamino)methyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-53-8 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(2,2-dimethyl-1,3-benzodioxol-5-yl)-4,5,6,7-tetrahydro-6-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 194098-59-4 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[6-(2-hydroxyethoxy)-3-pyridinyl]-6-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 194098-92-5 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-[2-(methylamino)ethoxy]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



L8 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2002 ACS  
 AN 1995:823078 CAPLUS  
 DN 123:313756  
 TI Preparation of annelated pyrrolocarboxanilides as GABA brain receptor ligands  
 IN Albaugh, Pamela; Hutchison, Alan  
 PA Neurogen Corp., USA  
 SO PCT Int. Appl., 66 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9511885	A1	19950504	WO 1994-US12300	19941026
	W:	AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ			
	RW:	KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN,			

		TD, TG			
US	5484944	A	19960116	US	1993-144138 19931027
CA	2175204	AA	19950511	CA	1994-2175204 19941026
AU	9481265	A1	19950522	AU	1994-81265 19941026
AU	701151	B2	19990121		
EP	725775	A1	19960814	EP	1995-900440 19941026
EP	725775	B1	19980722		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE					
CN	1143953	A	19970226	CN	1994-194657 19941026
JP	09506082	T2	19970617	JP	1994-512807 19941026
HU	76064	A2	19970630	HU	1996-1106 19941026
HU	219715	B	20010628		
EP	825193	A1	19980225	EP	1997-117241 19941026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE					
AT	168673	E	19980815	AT	1995-900440 19941026
ES	2122504	T3	19981216	ES	1995-900440 19941026
RU	2125989	C1	19990210	RU	1996-110289 19941026
RU	2157367	C2	20001010	RU	1998-115589 19941026
PL	180027	B1	20001229	PL	1994-314136 19941026
CZ	288027	B6	20010411	CZ	1996-1129 19941026
SE	9601563	A	19960522	SE	1996-1563 19960424
NO	9601655	A	19960610	NO	1996-1655 19960425
FI	9601776	A	19960614	FI	1996-1776 19960425
AU	9923799	A1	19990603	AU	1999-23799 19990416
AU	729634	B2	20010208		
SE	9902648	A	19990709	SE	1999-2648 19990709
PRAI	US 1993-144138	A2	19931027		
	AU 1994-81265	A3	19941026		
	EP 1995-900440	A3	19941026		
WO	1994-US12300	W	19941026		
OS	MARPAT 123:313756				
GI					



AB Title compds. [e.g., I; R = NHR<sub>1</sub>; R<sub>1</sub> = (un)substituted Ph, -thienyl, -pyridyl, etc.] were prepd. Thus, 1,3-cyclohexanedione was cyclocondensed with BrCH<sub>2</sub>COCO<sub>2</sub>Et and the product converted in 3 steps to I (R = OH) which was amidated by 4-(MeO)C<sub>6</sub>H<sub>4</sub>NH<sub>2</sub> to give I [R = NHC<sub>6</sub>H<sub>4</sub>(OMe)-4]. I [R = NHC<sub>6</sub>H<sub>4</sub>(OMe)F-4,2] had IC<sub>50</sub> of 0.001.μM against flumazenil binding at rat cortical tissue prepn. in vitro.

IT 168271-93-0P 168271-95-2P 168271-98-5P  
 168271-99-6P 168272-02-4P 168272-03-5P  
 168272-04-6P 168272-05-7P 168272-07-9P  
 168272-08-0P 168272-10-4P 168272-11-5P  
 168272-13-7P 168272-14-8P 168272-15-9P  
 168272-17-1P 168272-18-2P 168272-20-6P  
 168272-21-7P 168272-25-1P 168272-26-2P  
 168272-27-3P 168272-28-4P 168272-29-5P  
 168272-30-8P 168272-31-9P 168272-32-0P  
 168272-33-1P 168272-36-4P 168272-37-5P  
 168272-38-6P 168272-39-7P 168272-40-0P  
 168272-41-1P 168272-42-2P 168272-43-3P  
 168272-44-4P 168272-46-6P 168272-47-7P  
 168272-48-8P 168272-51-3P 168272-54-6P  
 168272-55-7P 168272-56-8P 168272-59-1P


168272-60-4P 168272-61-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of annelated pyrrolocarboxanilides as GABA brain receptor ligands)


RN 168271-93-0 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 168271-95-2 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168271-98-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-methoxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 168271-99-6 CAPLUS


CN 1H-Indole-3-carboxamide, N-(4-ethoxy-2-fluorophenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 168272-02-4 CAPLUS


CN 1H-Indole-3-carboxamide, N-(4-cyanophenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI)

(CA INDEX NAME)




RN 168272-03-5 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(3-methoxyphenyl)-4-oxo-  
(9CI) (CA INDEX NAME)




RN 168272-04-6 CAPLUS

CN 1H-Indole-3-carboxamide, N-[4-(acetylamino)phenyl]-4,5,6,7-tetrahydro-4-oxo-  
(9CI) (CA INDEX NAME)




RN 168272-05-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-chlorophenyl)-4,5,6,7-tetrahydro-4-oxo-  
(9CI) (CA INDEX NAME)




RN 168272-07-9 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-acetylphenyl)-4,5,6,7-tetrahydro-4-oxo-  
(9CI) (CA INDEX NAME)




RN 168272-08-0 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-5-methoxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-10-4 CAPLUS

CN Benzoic acid, 4-[[[(4,5,6,7-tetrahydro-4-oxo-1H-indol-3-yl)carbonyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 168272-11-5 CAPLUS

CN Benzoic acid, 4-[[[(4,5,6,7-tetrahydro-4-oxo-1H-indol-3-yl)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 168272-13-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-(3-ethoxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-14-8 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(1-methylethoxy)phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-15-9 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-fluorophenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-17-1 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-hydroxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-18-2 CAPLUS


CN 1H-Indole-3-carboxamide, N-(4-aminophenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-20-6 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(methoxymethyl)phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-21-7 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(3-fluoro-4-methoxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-25-1 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(2,2-dimethyl-1,3-benzodioxol-5-yl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 168272-26-2 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-[2-fluoro-4-(1-methylethoxy)phenyl]-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-27-3 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(4-fluorophenyl)-4,5,6,7-tetrahydro-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-28-4 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-methoxyphenyl)-4,5,6,7-tetrahydro-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-29-5 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-30-8 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(methoxymethyl)phenyl]-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-31-9 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-methoxyphenyl)-5,5-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-32-0 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(6-methoxy-3-pyridinyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-33-1 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(3,4-dihydroxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-36-4 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-hydroxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 168272-37-5 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(2-fluoro-4-methoxyphenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-38-6 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(4-ethoxy-2-fluorophenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-39-7 CAPLUS

CN 1H-Indole-3-carboxamide, N-(4-ethoxyphenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-40-0 CAPLUS

CN 1H-Indole-3-carboxamide, N-(2-amino-3-pyridinyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-41-1 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(4-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-42-2 CAPLUS


CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(3-methylphenyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-43-3 CAPLUS  
CN 1H-Indole-3-carboxamide, N-(2-amino-4-methylphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-44-4 CAPLUS  
CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(methylamino)phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-46-6 CAPLUS  
CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-(3-hydroxy-4-methoxyphenyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 168272-47-7 CAPLUS  
CN 1H-Indole-3-carboxamide, N-(2-fluorophenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-48-8 CAPLUS  
CN 1H-Indole-3-carboxamide, N-(3-fluorophenyl)-4,5,6,7-tetrahydro-6,6-dimethyl-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-51-3 CAPLUS

CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(2-methoxyethoxy)phenyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-54-6 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-(4-ethoxyphenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-55-7 CAPLUS

CN Cyclohepta[b]pyrrole-3-carboxamide, N-(2-fluorophenyl)-1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-56-8 CAPLUS


CN 1H-Indole-3-carboxamide, N-(7-chloro-1,8-naphthyridin-2-yl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)




RN 168272-59-1 CAPLUS  
 CN Cyclohepta[b]pyrrole-3-carboxamide, N-(2-fluoro-4-methoxyphenyl)-  
 1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 168272-60-4 CAPLUS  
 CN Cyclohepta[b]pyrrole-3-carboxamide, N-(4-ethoxy-2-fluorophenyl)-  
 1,4,5,6,7,8-hexahydro-4-oxo- (9CI) (CA INDEX NAME)



RN 168272-61-5 CAPLUS  
 CN 1H-Indole-3-carboxamide, N-(4-fluoro-2-hydroxyphenyl)-4,5,6,7-tetrahydro-4-oxo- (9CI) (CA INDEX NAME)



IT 168272-49-9P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of annelatepyrrolecarboxanilides as GABA brain receptor ligands)

RN 168272-49-9 CAPLUS  
 CN 1H-Indole-3-carboxamide, 4,5,6,7-tetrahydro-N-[4-(2-hydroxyethoxy)phenyl]-4-oxo- (9CI) (CA INDEX NAME)

